NZ752224B2 - Methods for treating nasal polyposis by administering an il-4r antagonist - Google Patents
Methods for treating nasal polyposis by administering an il-4r antagonist Download PDFInfo
- Publication number
- NZ752224B2 NZ752224B2 NZ752224A NZ75222414A NZ752224B2 NZ 752224 B2 NZ752224 B2 NZ 752224B2 NZ 752224 A NZ752224 A NZ 752224A NZ 75222414 A NZ75222414 A NZ 75222414A NZ 752224 B2 NZ752224 B2 NZ 752224B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- nasal
- score
- week
- antibody
- subject
- Prior art date
Links
- 230000003042 antagnostic Effects 0.000 title description 129
- 239000005557 antagonist Substances 0.000 title description 128
- 108090001123 antibodies Proteins 0.000 claims abstract description 173
- 102000004965 antibodies Human genes 0.000 claims abstract description 173
- 239000000427 antigen Substances 0.000 claims abstract description 101
- 108091007172 antigens Proteins 0.000 claims abstract description 100
- 102000038129 antigens Human genes 0.000 claims abstract description 100
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims abstract description 62
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims abstract description 62
- 201000009890 sinusitis Diseases 0.000 claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 43
- 230000001684 chronic Effects 0.000 claims abstract description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 208000006673 Asthma Diseases 0.000 claims description 109
- 208000000592 Nasal Polyps Diseases 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 42
- 210000003979 Eosinophils Anatomy 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 239000003246 corticosteroid Substances 0.000 claims description 35
- 238000002560 therapeutic procedure Methods 0.000 claims description 32
- 102100019494 CCL17 Human genes 0.000 claims description 21
- 108010082169 Chemokine CCL17 Proteins 0.000 claims description 21
- 238000002648 combination therapy Methods 0.000 claims description 18
- 229940114006 fluticasone / salmeterol Drugs 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000002146 bilateral Effects 0.000 claims description 15
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 14
- 229960002714 fluticasone Drugs 0.000 claims description 14
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims description 13
- 206010027590 Middle insomnia Diseases 0.000 claims description 13
- 229960002848 formoterol Drugs 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 12
- 229960002744 mometasone furoate Drugs 0.000 claims description 12
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 12
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims description 12
- 230000035943 smell Effects 0.000 claims description 12
- 102100008431 CCL26 Human genes 0.000 claims description 11
- 108010083698 Chemokine CCL26 Proteins 0.000 claims description 11
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 206010036790 Productive cough Diseases 0.000 claims description 10
- 210000003802 Sputum Anatomy 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 230000000007 visual effect Effects 0.000 claims description 10
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 claims description 9
- 210000004086 Maxillary Sinus Anatomy 0.000 claims description 9
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 9
- 229940080593 Budesonide / formoterol Drugs 0.000 claims description 8
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 8
- 229960001334 Corticosteroids Drugs 0.000 claims description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 8
- 239000000850 decongestant Substances 0.000 claims description 8
- 230000009610 hypersensitivity Effects 0.000 claims description 8
- 239000007922 nasal spray Substances 0.000 claims description 8
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 8
- 229940097496 Nasal Spray Drugs 0.000 claims description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 7
- 230000003247 decreasing Effects 0.000 claims description 7
- 230000000699 topical Effects 0.000 claims description 7
- 229960004436 Budesonide Drugs 0.000 claims description 6
- 102100012988 CHI3L1 Human genes 0.000 claims description 6
- 101710031591 CHI3L1 Proteins 0.000 claims description 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 6
- 229960004017 salmeterol Drugs 0.000 claims description 6
- 102100013748 POSTN Human genes 0.000 claims description 5
- 101700019061 POSTN Proteins 0.000 claims description 5
- 230000001387 anti-histamine Effects 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 230000003444 anaesthetic Effects 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000003434 inspiratory Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 238000003551 nucleic acid identification and quantitation method Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229940090047 Auto-Injector Drugs 0.000 claims description 3
- 108090001124 Immunoglobulin E Proteins 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- YECBIJXISLIIDS-UHFFFAOYSA-N Mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 2
- 101710028361 MARVELD2 Proteins 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 74
- 229940068196 placebo Drugs 0.000 description 74
- 230000035492 administration Effects 0.000 description 54
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 42
- 230000005713 exacerbation Effects 0.000 description 28
- 230000002354 daily Effects 0.000 description 26
- 230000004044 response Effects 0.000 description 26
- 206010039101 Rhinorrhoea Diseases 0.000 description 24
- 239000000090 biomarker Substances 0.000 description 23
- 241000565118 Cordylophora caspia Species 0.000 description 21
- 206010061529 Polyp Diseases 0.000 description 21
- 210000004602 germ cell Anatomy 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 238000002591 computed tomography Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 231100000494 adverse effect Toxicity 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 238000004166 bioassay Methods 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 230000002829 reduced Effects 0.000 description 16
- 210000002966 Serum Anatomy 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 14
- 229940023808 Albuterol Drugs 0.000 description 13
- 206010009137 Chronic sinusitis Diseases 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 13
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 13
- 229960002052 salbutamol Drugs 0.000 description 13
- 230000003442 weekly Effects 0.000 description 13
- 230000036541 health Effects 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 210000004369 Blood Anatomy 0.000 description 11
- 206010039083 Rhinitis Diseases 0.000 description 11
- 230000002378 acidificating Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940079593 drugs Drugs 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000000414 obstructive Effects 0.000 description 11
- 230000002085 persistent Effects 0.000 description 11
- 230000008786 sensory perception of smell Effects 0.000 description 11
- 150000003431 steroids Chemical class 0.000 description 11
- 229950003468 Dupilumab Drugs 0.000 description 10
- 229940087612 Levalbuterol Drugs 0.000 description 10
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 10
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 10
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 10
- 201000009910 diseases by infectious agent Diseases 0.000 description 10
- 108091003598 dupilumab Proteins 0.000 description 10
- 238000001839 endoscopy Methods 0.000 description 10
- 229950008204 levosalbutamol Drugs 0.000 description 10
- 230000001264 neutralization Effects 0.000 description 10
- 210000004027 cells Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 102100011842 CEACAM5 Human genes 0.000 description 8
- 210000003928 Nasal Cavity Anatomy 0.000 description 8
- 206010028735 Nasal congestion Diseases 0.000 description 8
- 206010028748 Nasal obstruction Diseases 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- -1 domain-deleted dies Proteins 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000000977 initiatory Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 231100000247 serious adverse effect Toxicity 0.000 description 8
- 206010016059 Facial pain Diseases 0.000 description 7
- 210000001331 Nose Anatomy 0.000 description 7
- 230000000172 allergic Effects 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000011068 load Methods 0.000 description 7
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 6
- 230000001154 acute Effects 0.000 description 6
- 230000002009 allergen Effects 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 230000001419 dependent Effects 0.000 description 6
- 230000002327 eosinophilic Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 206010001076 Acute sinusitis Diseases 0.000 description 5
- 229940090167 Advair Drugs 0.000 description 5
- 206010002653 Anosmia Diseases 0.000 description 5
- 102000018358 Immunoglobulins Human genes 0.000 description 5
- 108060003951 Immunoglobulins Proteins 0.000 description 5
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 229960001664 Mometasone Drugs 0.000 description 5
- 210000003695 Paranasal Sinuses Anatomy 0.000 description 5
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 210000001944 Turbinates Anatomy 0.000 description 5
- 206010047924 Wheezing Diseases 0.000 description 5
- 201000010105 allergic rhinitis Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 5
- 230000003285 pharmacodynamic Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 206010060945 Bacterial infection Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 102000002802 Eosinophil Cationic Protein Human genes 0.000 description 4
- 108010004612 Eosinophil Cationic Protein Proteins 0.000 description 4
- 208000002672 Hepatitis B Diseases 0.000 description 4
- 206010037844 Rash Diseases 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000002596 correlated Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000004199 lung function Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 108090000298 Antinuclear Antibodies Proteins 0.000 description 3
- 101700075350 CDRB Proteins 0.000 description 3
- 206010071380 Chronic hyperplastic eosinophilic sinusitis Diseases 0.000 description 3
- 230000037242 Cmax Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 229940103439 Dulera Drugs 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
- 241000725581 Frog erythrocytic virus Species 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 229940003691 Nasonex Drugs 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 208000006551 Parasitic Disease Diseases 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 229940035073 Symbicort Drugs 0.000 description 3
- 210000001541 Thymus Gland Anatomy 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- YYAZJTUGSQOFHG-RZFXJYHSSA-N [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino] Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-RZFXJYHSSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 230000002538 fungal Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000391 smoking Effects 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001052 transient Effects 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 2
- 206010002425 Angioedemas Diseases 0.000 description 2
- 208000001097 Ankle Fracture Diseases 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 206010004938 Bipolar disease Diseases 0.000 description 2
- 102100019487 CCL11 Human genes 0.000 description 2
- 101700074178 CCL11 Proteins 0.000 description 2
- 208000001590 Congenital Abnormality Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229960003722 Doxycycline Drugs 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 206010015037 Epilepsy Diseases 0.000 description 2
- 229940085861 Flovent Drugs 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 206010019233 Headache Diseases 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 210000004969 Inflammatory Cells Anatomy 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 229940028885 Interleukin-4 Drugs 0.000 description 2
- 229940100602 Interleukin-5 Drugs 0.000 description 2
- 229960002329 Methacholine Drugs 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 229960000470 Omalizumab Drugs 0.000 description 2
- 108010029597 Omalizumab Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 208000008128 Pulmonary Tuberculosis Diseases 0.000 description 2
- 235000015076 Shorea robusta Nutrition 0.000 description 2
- 206010040744 Sinus headache Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229940076185 Staphylococcus aureus Drugs 0.000 description 2
- 229960000278 Theophylline Drugs 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- 230000001889 chemoattractant Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 230000000306 recurrent Effects 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 230000035489 relative bioavailability Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-Furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 108010038809 AMG 317 Proteins 0.000 description 1
- 229940005497 ANTICHOLINERGIC AGENTS Drugs 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010082126 Alanine Transaminase Proteins 0.000 description 1
- 206010001584 Alcohol abuse Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 description 1
- 240000000800 Allium ursinum Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010003486 Aspergillus infection Diseases 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004161 Basedow's disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010061590 Blood disease Diseases 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100013076 CD48 Human genes 0.000 description 1
- 101700012453 CD48 Proteins 0.000 description 1
- 101700027814 CDR3 Proteins 0.000 description 1
- 102100009641 CXCL10 Human genes 0.000 description 1
- 101710032181 CXCL10 Proteins 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 210000003467 Cheek Anatomy 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010071399 Chronic eosinophilic rhinosinusitis Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- 229940009997 Cromolyn Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010012378 Depression Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 102000004420 EC 2.7.3.2 Human genes 0.000 description 1
- 108010042126 EC 2.7.3.2 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014551 Emotional disease Diseases 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229940015979 Epipen Drugs 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 210000001180 Ethmoid Sinus Anatomy 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 210000001214 Frontal Sinus Anatomy 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100010966 GPT Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 208000004551 Gunshot Wounds Diseases 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010008147 Hepatitis C Antibodies Proteins 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 229940062714 Humalog Mix Drugs 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102100005027 IL1RN Human genes 0.000 description 1
- 101710007852 IL1RN Proteins 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022056 Injection site dermatitis Diseases 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 206010022066 Injection site haematoma Diseases 0.000 description 1
- 206010057880 Injection site nodule Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010022093 Injection site pruritus Diseases 0.000 description 1
- 206010022094 Injection site rash Diseases 0.000 description 1
- 206010022095 Injection site reaction Diseases 0.000 description 1
- 206010022107 Injection site urticaria Diseases 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- 229960001361 Ipratropium Bromide Drugs 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- 208000003892 Kartagener Syndrome Diseases 0.000 description 1
- 101700064702 LABA Proteins 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229940065725 Leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 230000036917 MEAN CMAX Effects 0.000 description 1
- 229940014456 MYCOPHENOLATE Drugs 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229960005162 Oxymetazoline hydrochloride Drugs 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 229940090048 Pen Injector Drugs 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 230000036885 QTc Effects 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 102100010891 RTN4IP1 Human genes 0.000 description 1
- 101710017930 RTN4IP1 Proteins 0.000 description 1
- 241000271569 Rhea Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 101710044433 SAG Proteins 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010041232 Sneezing Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000003718 Sphenoid Sinus Anatomy 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- 231100000617 Superantigen Toxicity 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 208000005057 Thyrotoxicosis Diseases 0.000 description 1
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 229940116269 Uric Acid Drugs 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 206010046736 Urticarias Diseases 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010063689 Young's syndrome Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000001270 agonistic Effects 0.000 description 1
- 201000010000 agranulocytosis Diseases 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 201000003082 alcohol use disease Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 201000002909 aspergillosis Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000001886 ciliary Effects 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 229940000406 drug candidates Drugs 0.000 description 1
- 230000000142 dyskinetic Effects 0.000 description 1
- 230000002497 edematous Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial Effects 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 238000010358 genetic engineering technique Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 201000002138 hematopoietic system disease Diseases 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000010229 hepatobiliary disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 201000002563 histoplasmosis Diseases 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000002390 hyperplastic Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000420 mucociliary Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000422 nocturnal Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 230000003071 parasitic Effects 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002974 pharmacogenomic Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- ORMNNUPLFAPCFD-MPQOODJTSA-M potassium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-phenoxypropanoyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].O([C@H](C)C(=O)N[C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C1=CC=CC=C1 ORMNNUPLFAPCFD-MPQOODJTSA-M 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 201000009266 primary ciliary dyskinesia Diseases 0.000 description 1
- 230000001823 pruritic Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Disclosed is the use of an antibody or antigen binding fragment thereof, that specifically binds an interleukin-4 receptor (IL-4R) for the preparation of a pharmaceutical composition for treating nasal polyposis in a subject, and wherein the antibody or antigen-binding fragment thereof comprises three HCDRs and three LCDRs, wherein the HCDR1 comprises SEQ ID NO:3, the HCDR2 comprises SEQ ID NO:4, the HCDR3 comprises SEQ ID NO:5, the LCDR1 comprises SEQ ID NO:6, the LCDR2 comprises SEQ ID NO:7, and the LCDR3 comprises SEQ ID NO:8. In a preferred embodiment the pharmaceutical composition is prepared to treat chronic rhinosinusitis with nasal polyposis. ee HCDRs and three LCDRs, wherein the HCDR1 comprises SEQ ID NO:3, the HCDR2 comprises SEQ ID NO:4, the HCDR3 comprises SEQ ID NO:5, the LCDR1 comprises SEQ ID NO:6, the LCDR2 comprises SEQ ID NO:7, and the LCDR3 comprises SEQ ID NO:8. In a preferred embodiment the pharmaceutical composition is prepared to treat chronic rhinosinusitis with nasal polyposis.
Description
METHODS FOR TREATING NASAL POLYPOSIS BY ADMINISTERING AN |L-4R
NIST
RELATED APPLICATIONS
This ation claims the benefit of US. Provisional Application No. 61/837,912, filed
June 21, 2013 and European Application No. 143056703, filed May 7, 2014, each of which is
incorporated herein by reference in its ty.
FIELD OF THE INVENTION
The present invention relates to the field of therapeutic treatments of inflammatory
ions. More specifically, the invention relates to the administration of interleukin-4 or
(IL-4R) antagonists to treat nasal polyposis.
BACKGROUND
Nasal sis (NP) is a clinical condition characterized by the presence of le
polyps in the upper nasal cavity, originating from the ostiomeatal complex. NP is a T helper cell-
2 (Th-2) driven inflammatory process affecting the mucosa of the nose and paranasal sinuses.
Eosinophils and their products are thought to be a hallmark of nasal polyp-associated
inflammation as elevated levels of interleukin-5 (IL-5; promotes eosinophil survival and
differentiation), eosinophil cationic protein (ECP), and eotaxin (eosinophil chemoattractant),
factors that attract and te eosinophils, are typically found in nasal polyps. Eosinophils are
the predominant inflammatory cell found in the sinuses and nasal polyps, and nasal polyps are
also associated with elevated levels of lgE. NP is characterized by long-term symptoms of
nasal obstruction and congestion, reduction in or loss of sense of smell, anterior and posterior
rhinorrhea, and facial pain. Current treatment options range from local or ic
corticosteroids to functional endoscopic sinus surgery.
BRIEF SUMMARY OF THE INVENTION
[0004] In one aspect, the invention provides a method for treating nasal polyposis, where the
method includes administering to a subject in need thereof a pharmaceutical composition
containing an eukin-4 receptor (IL-4R) antagonist, such as an L-4R antibody or
n-binding fragment thereof. In one embodiment, the lL-4R antagonist is an antibody or
antigen-binding fragment thereof that specifically binds lL-4Rd, such as an antibody or antigen
binding fragment that comprises heavy and light chain CDR sequences from a heavy chain
variable region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID
NO:2. For example, in one embodiment, the antibody or antigen binding fragment thereof
comprises heavy chain CDR ces of SEQ ID NOs:3, 4, and 5, and light chain CDR
sequences of SEQ ID NOs:6, 7 and 8. For example, in one embodiment, the antibody or
antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ
ID NO:1 and an LCVR having the amino acid ce of SEQ ID NO:2. In one embodiment,
the lL-4R antagonist is dupilumab or an n-binding fragment thereof. Other exemplary anti-
IL-4R dies or antigen-binding fragments thereof are bed, for example, in US Patent
Nos. 7,605,237 and 7,608,693.
A subject suitable for treatment with an IL-4R antagonist may have one or more of
sinusitis, is, asthma, aspirin hypersensitivity, non-steroidal anti-inflammatory drug (NSAID)
hypersensitivity, or have previously undergone surgery to treat nasal polyposis. In some
embodiments, the subject has c tis or chronic rhinosinusitis. For example, the
subject may have nasal polyposis with severe symptoms of sinusitis.
In some embodiments, the IL-4R antagonist is administered at a dose of 0.1 mg to 600
mg (e.g., 100 mg to 400 mg, such as 150 mg, 200 mg, 250 mg, 300 mg or 350 mg). In n
embodiments, the pharmaceutical composition is administered to the subject systemically or
locally. For example, the pharmaceutical composition may be administered subcutaneously,
intravenously, or asally.
In one embodiment, the pharmaceutical ition is administered to the subject
subcutaneously at a dose of 300 mg.
In certain embodiments, one or more additional therapeutic agents are administered to
the subject , after or concurrent with the pharmaceutical composition sing the IL-4R
antagonist, such as the IL-4R antibody or n-binding fragment thereof. For example, in one
ment, the one or more additional agents, such as a second therapeutic agent can be a
TNF inhibitor, an lL-1 inhibitor, an lL-5 inhibitor, an lL-8 inhibitor, an lgE inhibitor, an NSAID
(non-steroidal nflammatory drug), an otic, an anti-fungal agent, an intranasal
corticosteroid, an inhaled corticosteroid, a systemic corticosteroid, a long-acting beta2 agonist, a
decongestant, or any combination thereof. In one embodiment, the second therapeutic agent is
an inhaled corticosteroid, such as fluticasone or budesonide, or an intranasal corticosteroid,
such as mometasone furoate nasal spray (MFNS). In another embodiment, the second
therapeutic agent further includes a long-acting beta2 agonist, such as erol or formoterol.
In certain embodiments, administration of the IL-4R antagonist is followed by an
improvement in one or more symptoms of nasal polyposis. For example, the administration of
the antagonist can be followed by an improvement in one or more nasal polyposis-associated
parameters, such as an improvement in a 22—item Sinonasal Outcome Test (SNOT-22) score; a
nasal symptom score; number of nocturnal awakenings; a Visual Analog Score (VAS), such as
for rhinosinusitis symptom severity; a five-item Asthma Control Questionnaire (ACQS) score;
nasal peak inspiratory flow (NPIF); the University of Pennsylvania Smell Identification Test
(UPSIT); Lund-McKay Score; and three dimensional volumetric measurement of the maxillary
sinus. In certain embodiments, administration of the antibody or antigen binding fragment
thereof is followed by one or more of an increase in one or both of NPIF and UPSIT, and a
decrease in one or more of SNOT-22 score, nasal symptom score, VAS, Lund-McKay Score
and 3D-Volumetric Score. In some embodiments, administration of the lL-4R antagonist is
followed by a decrease in nasal polyp score in the patient.
In one aspect, the ion provides a method for treating nasal polyposis, by
sequentially administering to a subject in need thereof a single initial dose of an interleukin-4
receptor (IL-4R) antagonist, such as an lL-4R antibody or an antigen-binding fragment thereof,
followed by one or more secondary doses of the lL-4R antagonist. In some embodiments, each
secondary dose is administered 1 to 15 weeks after the immediately preceding dose. In other
embodiments, at least three secondary doses of the lL-4R antagonist are administered to the
subject, and each secondary dose is administered days or weeks (e.g., 1 week or 2 weeks or
more) after the immediately preceding dose. In another embodiment, the initial dose and the
one or more secondary doses each include 50 mg to 500 mg of the lL-4R antagonist, e.g., 100
mg to 400 mg of the lL-4R antagonist, e.g., 150 mg, 200 mg, 250 mg, 300 mg, or 350 mg of the
lL-4R antagonist. In some embodiments, the initial dose and the one or more secondary doses
each n the same amount of the lL-4R antagonist. In other embodiments, the initial dose
comprises a first amount of the lL-4R antagonist, and the one or more secondary doses each
comprise a second amount of the lL-4R antagonist. For example, the first amount of the lL-4R
antagonist can be 1.5x, 2x, 2.5x, 3x, 3.5x, 4x or 5x or more than the second amount of lL-4R
nist.
[0011] In one embodiment, the subject (e.g., a patient) has one or more of sinusitis, rhinitis,
asthma, aspirin hypersensitivity, non-steroidal nflammatory drug (NSAID) hypersensitivity,
or has undergone surgery for nasal polyps. In some embodiments, the subject has chronic
sinusitis or c rhinosinusitis. For example, the subject may have nasal polyposis with
severe symptoms of tis.
[0012] The initial dose and the secondary doses of the lL-4R antagonist can be administered
by the same or different routes of administration. For example, the initial dose and the
secondary doses can be stered subcutaneously, intravenously, or intranasally.
In certain embodiments, administration of the initial dose and the one or more
secondary doses is followed by an improvement in one or more nasal polyposis associated
parameters, such as an improvement in a 22—item Sinonasal e Test (SNOT-22) score; a
nasal m score; number of nocturnal awakenings; a Visual Analog Score (VAS), such as
for rhinosinusitis symptom ty; a tem Asthma Control Questionnaire (ACQ5) score;
nasal peak inspiratory flow (NPIF); the sity of Pennsylvania Smell fication Test
(UPSIT); Lund-McKay Score; and three dimensional volumetric measurement of the maxillary
sinus. In certain embodiments, administration of the antibody or antigen g fragment
thereof is followed by one or more of an increase in one or both of NPIF and UPSIT, and a
decrease in one or more of SNOT-22 score, nasal symptom score, VAS, Lund-McKay Score
and 3D-Volumetric Score. In some embodiments, administration of the IL-4R antagonist is
ed by a decrease in nasal polyp score in the patient.
In certain embodiments, one or more additional therapeutic agents are administered to
the subject before, after or concurrent with the pharmaceutical composition comprising the IL-4R
antagonist, such as the IL-4R antibody or antigen-binding fragment thereof. For example, in one
embodiment, the one or more additional , such as a second therapeutic agent can be a
TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an lgE inhibitor, an NSAID, an
antibiotic, an ungal agent, an intranasal corticosteroid, an d corticosteroid, a systemic
corticosteroid, a long-acting beta2 agonist, a decongestant, or any combination thereof. In one
embodiment, the second therapeutic agent is an inhaled corticosteroid, such as fluticasone or
budesonide, or an intranasal corticosteroid, such as mometasone furoate nasal spray (MFNS).
In another embodiment, the second therapeutic agent further includes a long-acting beta2
agonist, such as erol or formoterol.
In one aspect, the invention provides a method for treating nasal polyposis, by
selecting a patient with a m bilateral nasal polyp score of 5, or at least two or more of the
chronic symptoms of sinusitis selected from the group consisting of: nasal
blockade/obstruction/congestion, or or posterior nasal drip, facial pain or pressure, and
reduction or loss of smell; and administering to the selected patient a pharmaceutical
composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as antibody or
antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R), such
that the patient’s nasal polyp score is reduced or the two or more chronic symptoms of sinusitis
are improved. In one embodiment, the IL-4R nist is an antibody or antigen-binding
fragment thereof that specifically binds , such as an antibody or antigen binding fragment
that comprises heavy and light chain CDR sequences from a heavy chain variable region
(HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2. For
e, in one ment, the dy or antigen binding fragment f comprises heavy
chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID
NOs:6, 7 and 8. For example, in one embodiment, the antibody or antigen-binding fragment
thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR
having the amino acid ce of SEQ ID NO:2. In one embodiment, the IL-4R antagonist is
mab or an antigen-binding fragment thereof. Other exemplary anti-IL-4R antibodies or
antigen-binding fragments f are described, for example, in US Patent Nos. 7,605,237 and
7,608,693.
In one , the invention provides a method for treating nasal polyposis, by
selecting a patient with a minimum bilateral nasal polyp score of 5, or at least two or more of the
chronic symptoms of sinusitis selected from the group consisting of: nasal
blockade/obstruction/congestion, anterior or posterior nasal drip, facial pain or pressure, and
reduction or loss of smell; and sequentially administering to the patient a single initial dose of a
pharmaceutical composition an interleukin-4 receptor (IL-4R) antagonist, such as antibody or
antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R),
followed by one or more secondary doses of the antibody or antigen binding fragment thereof,
such that the patient’s nasal polyp score is reduced or the two or more chronic symptoms of
tis are improved. In one embodiment, the lL-4R antagonist is an antibody or antigen-
binding nt thereof that ically binds lL-4Rd, such as an antibody or antigen binding
fragment that comprises heavy and light chain CDR sequences from a heavy chain variable
region (HCVR) of SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2. For
example, in one embodiment, the antibody or antigen binding fragment thereof comprises heavy
chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR sequences of SEQ ID
NOs:6, 7 and 8. For example, in one embodiment, the dy or antigen-binding fragment
f ses an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR
having the amino acid sequence of SEQ ID NO:2. In one embodiment, the lL-4R antagonist is
dupilumab or an antigen-binding fragment thereof. Other exemplary anti-IL-4R antibodies or
antigen-binding fragments thereof are described, for example, in US Patent Nos. 237 and
7,608,693.
In one aspect, the invention provides a method for treating nasal polyposis, by
determining in a subject the expression level of one or more genes selected from the group
consisting of thymus and activation-regulated chemokine (TARC), eotaxin-3, periostin,
carcinoembryonic antigen (CEA), and ; selecting the subject as a candidate for treatment
with an interleukin-4 receptor ) nist, such as antibody or n-binding fragment
thereof that specifically binds an interleukin-4 receptor (IL-4R), if the subject has an elevated
expression level of the one or more genes; and administering to the selected subject a
pharmaceutical composition comprising an antibody or antigen binding fragment thereof that
specifically binds an interleukin-4 receptor (IL-4R), such that the level of the one or more genes
is reduced. In one embodiment, the lL-4R antagonist is an antibody or antigen-binding fragment
thereof that specifically binds lL-4Rd, such as an antibody or antigen binding fragment that
comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of
SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2. For example, in one
ment, the antibody or antigen binding fragment thereof comprises heavy chain CDR
sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR ces of SEQ ID NOs:6, 7 and
8. For example, in one embodiment, the antibody or antigen-binding fragment thereof
ses an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the
amino acid sequence of SEQ ID NO:2. In one ment, the lL-4R antagonist is dupilumab
or an antigen-binding nt thereof. Other exemplary L-4R antibodies or antigen-
binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and
7,608,693.
In one aspect, the invention provides a method for treating nasal polyposis, by
determining in a subject the expression level of one or more genes ed from the group
consisting of thymus and tion-regulated chemokine (TARC), eotaxin-3, periostin,
carcinoembryonic antigen (CEA), and YKL-40; selecting the subject as a candidate for treatment
with an interleukin-4 receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment
f that specifically binds an interleukin-4 or (IL-4R), if the subject has an elevated
expression level of the one or more genes; and sequentially administering to the selected
subject a single initial dose of a pharmaceutical composition comprising an interleukin-4
receptor (IL-4R) antagonist, such as antibody or antigen-binding fragment thereof that
ically binds an interleukin-4 receptor (IL-4R), followed by one or more secondary doses of
the antibody or antigen binding fragment thereof, such that the level of the one or more genes is
reduced. In one embodiment, the IL-4R antagonist is an antibody or antigen-binding fragment
thereof that specifically binds IL-4Rd, such as an antibody or antigen g fragment that
comprises heavy and light chain CDR sequences from a heavy chain variable region (HCVR) of
SEQ ID NO:1, and a light chain variable region (LCVR) of SEQ ID NO:2. For e, in one
embodiment, the antibody or antigen binding fragment thereof comprises heavy chain CDR
sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR ces of SEQ ID NOs:6, 7 and
8. For example, in one embodiment, the antibody or antigen-binding fragment thereof
comprises an HCVR having the amino acid sequence of SEQ ID NO:1 and an LCVR having the
amino acid sequence of SEQ ID NO:2. In one embodiment, the IL-4R antagonist is dupilumab
or an antigen-binding fragment f. Other exemplary anti-IL-4R antibodies or antigen-
binding fragments thereof are described, for example, in US Patent Nos. 7,605,237 and
7,608,693.
In one aspect, the invention provides a method for treating nasal polyposis, by
determining in a subject the level of blood eosinophils or sputum eosinophils; selecting the
t as a candidate for treatment with an interleukin-4 receptor (IL-4R) antagonist, such as
dy or n-binding nt thereof that specifically binds an interleukin-4 receptor (IL-
4R), if the subject has an elevated level of blood eosinophils or sputum eosinophils; and
administering to the selected subject a pharmaceutical composition comprising an interleukin-4
receptor ) antagonist, such as antibody or antigen-binding fragment thereof that
specifically binds an interleukin-4 receptor (IL-4R), such that the level of blood eosinophils or
sputum eosinophils is reduced. In one embodiment, the IL-4R nist is an antibody or
antigen-binding fragment thereof that specifically binds IL-4Rd, such as an antibody or antigen
binding fragment that ses heavy and light chain CDR sequences from a heavy chain
variable region (HCVR) of SEQ ID NO:1, and a light chain le region (LCVR) of SEQ ID
NO:2. For example, in one embodiment, the antibody or n g fragment thereof
comprises heavy chain CDR sequences of SEQ ID NOs:3, 4, and 5, and light chain CDR
sequences of SEQ ID NOs:6, 7 and 8. For example, in one embodiment, the antibody or
antigen-binding nt f comprises an HCVR having the amino acid sequence of SEQ
ID NO:1 and an LCVR having the amino acid sequence of SEQ ID NO:2. In one embodiment,
the lL-4R antagonist is dupilumab or an antigen-binding fragment thereof. Other ary anti-
IL-4R antibodies or n-binding fragments thereof are described, for example, in US Patent
Nos. 7,605,237 and 7,608,693.
In one aspect, the invention es a method for treating nasal polyposis, by
determining in a subject the level of blood eosinophils or sputum eosinophils; selecting the
subject as a ate for treatment with an interleukin-4 receptor (IL-4R) antagonist, such as
antibody or antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-
4R), if the subject has an elevated level of blood eosinophils or sputum eosinophils; and
sequentially administering to the selected subject a single initial dose of a pharmaceutical
composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as antibody or
antigen-binding fragment thereof that specifically binds an interleukin-4 receptor (IL-4R),
followed by one or more secondary doses of the antibody or antigen binding fragment thereof,
such that the level of blood phils or sputum eosinophils is d. In one embodiment,
the IL-4R antagonist is an antibody or antigen-binding fragment thereof that specifically binds IL-
4Ror, such as an antibody or antigen binding fragment that comprises heavy and light chain CDR
sequences from a heavy chain variable region (HCVR) of SEQ ID NO:1, and a light chain
le region (LCVR) of SEQ ID NO:2. For example, in one embodiment, the antibody or
antigen binding fragment thereof comprises heavy chain CDR sequences of SEQ ID NOs:3, 4,
and 5, and light chain CDR sequences of SEQ ID NOs:6, 7 and 8. For example, in one
embodiment, the antibody or antigen-binding fragment thereof comprises an HCVR having the
amino acid sequence of SEQ ID NO:1 and an LCVR having the amino acid sequence of SEQ ID
NO:2. In one ment, the lL-4R antagonist is dupilumab or an n-binding fragment
thereof. Other exemplary anti-IL-4R antibodies or antigen-binding fragments thereof are
described, for example, in US Patent Nos. 7,605,237 and 7,608,693.
Other embodiments will become apparent from the below figure and the Detailed
Description.
BRIEF DESCRIPTION OF THE FIGURES
shows the schematic representation of an example of ound therapy
withdrawal time period in the ent of an asthma patient.
DETAILED DESCRIPTION
Before the present invention is described, it is to be understood that this invention is not
limited to particular s and mental conditions bed, as such methods and
conditions may vary. It is also to be understood that the terminology used herein is for the
purpose of describing particular embodiments only, and is not intended to be limiting.
Unless d otherwise, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
belongs. As used herein, the term "about," when used in reference to a particular recited
cal value, means that the value may vary from the recited value by no more than 1%. For
example, as used herein, the expression "about 100" includes 99 and 101 and all values in
between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
All publications mentioned herein are incorporated herein by reference in their entirety.
Methods for Treating Nasal Polyposis
[0026] The present ion provides s for treating nasal polyposis. As used herein, a
"nasal polyp" is an owth of tissue in one or more of the nasal cavities. The condition of
nasal polyps is called “nasal polyposis.” About 80% of nasal polyps are highly edematous and
filled with eosinophils. Nasal polyps can also present as fibrous, glandular or cystic.
Nasal polyposis (NP) is a clinical condition characterized by the presence of multiple
polyps in the upper nasal , originating from the ostiomeatal complex. NP is a T helper cell-
2 (Th-2) driven inflammatory process ing the mucosa of the nose and paranasal sinuses.
Eosinophils and their products are t to be a hallmark of nasal polyp-associated
inflammation as elevated levels of interleukin-5 (IL-5; promotes eosinophil survival and
differentiation), eosinophil cationic protein (ECP), and eotaxin (eosinophil chemoattractant),
factors that attract and activate eosinophils, are typically found in nasal polyps. Eosinophils are
the predominant inflammatory cell found in the sinuses and nasal polyps, and nasal polyps are
also associated with ed levels of lgE.
NP is characterized by erm symptoms of nasal obstruction and congestion,
reduction in or loss of sense of smell, anterior and ior rhinorrhea, and facial pain. The
presence or absence of nasal polyps can be confirmed for example by performing endoscopy,
and the presence and extent of sinus and polyp involvement can be confirmed by methods such
as coronal computed tomography (CT) scans.
An lL-4R antagonist can be used to treat nasal polyposis associated with a variety of
conditions. For example, nasal polyposis is associated with sinusitis, rhinitis (e.g., allergic and
non-allergic is), asthma (e.g., moderate-to-severe asthma), NSAID sensitivity (e.g., aspirin
sensitivity), and infection, such as bacterial and fungal infection. Bacterial infections include, for
example, staphylococcus infections. A subject with nasal polyposis can have a chronic
infection, such as a chronic bacterial infection, e.g., a chronic staphylococcus aureus infection.
In some embodiments, the subject has recurring nasal polyposis, such as may be associated
with recurring sinusitis. In other embodiments, the subject as cystic fibrosis or NARES (Non-
Allergic Rhinitis with Eosinophilia Syndrome). In other embodiments, the subject has a relapse
of nasal polyposis after receiving surgery to treat the polyps. Risk factors for nasal polyposis
include genetic susceptibility, anatomic abnormality, mucociliary impairment, infection, and local
immunologic imbalance.
An lL-4R nist can also be used to treat nasal polyposis in patients who have
never previously received a ent or surgery for NP. An lL-4R antagonist can also be used
to treat nasal polyposis in patients who have usly undergone surgery, such as a nasal
surgery, such as for treatment of nasal polyps. In certain ments, an lL-4R antagonist is
administered to a subject whose nasal polyposis has relapsed after the subject received prior
treatment for the polyps, such as a prior nasal surgery.
As used herein, the term “sinusitis” refers to any inflammatory condition characterized
by inflammation of the paranasal sinuses, including mation of the ary, frontal,
ethmoid and/or sphenoid paranasal sinuses. An lL-4R antagonist is suitable for treatment of
nasal polyposis is associated with acute sinusitis, subacute sinusitis, chronic sinusitis and
recurrent sinusitis. Acute sinusitis is characterized by a sudden onset of cold-like ms
such as runny, stuffy nose and facial pain that does not go away after 10 to 14 days. Acute
sinusitis typically lasts less than four weeks. Subacute sinusitis lasts four to eight weeks.
Chronic sinusitis lasts eight weeks or longer, and recurrent sinusitis is characterized by sinusitis
es that occur three or more times in one year. More than 80% of patients with c
tis with nasal polyps have eosinophilic upper airway inflammation.
Many patients with chronic sinusitis have “chronic hyperplastic eosinophilic sinusitis,”
which is terized by marked inflammation of the sinuses, increased eosinophils and mixed
mononuclear cells, and a relative paucity of neutrophils. Some of these patients have one or
more of ated nasal polyps, asthma, and aspirin or NSAID sensitivity. In certain
embodiments, an lL-4R antagonist can be used to treat nasal polyposis in a subject who has
chronic hyperplastic eosinophilic sinusitis.
The term “rhinitis” refers to an allergic response, such as to a common allergen
(“allergic rhinitis,” e.g., perennial allergic rhinitis) or to an environmental irritant allergic
rhinitis”). Symptoms of allergic rhinitis include sneezing; stuffy or runny nose; sinus pressure,
and pain or throbbing in the cheeks or nose; and g in the nose, throat, eyes and ears.
Symptoms of non-allergic is include constriction or inflammation in the nasal
passages which leads to many of the same symptoms of allergic rhinitis. lergic rhinitis can
be caused, for e, by strong chemical or smoky environments, or by erm use of
certain medications or dependency on nasal sprays.
As used herein, the term “rhinosinusitis” refers to a condition that has ms of both
rhinitis and sinusitis. Rhinosinusitis includes acute rhinosinusitis and chronic rhinosinusitis.
Acute rhinosinusitis can be caused by an infection, such as a bacterial, viral or fungal infection,
or by a chemical tion. Cigarette-smoke-induced acute inusitis and chlorine fume-
induced chronic rhinosinusitis are examples of acute rhinosinusitis. NP is most commonly
associated with chronic rhinosinusitis (CRS), which is characterized by mucosal inflammation of
the nasal cavity and paranasal sinuses with symptoms lasting more than 8 weeks. Chronic
eosinophilic rhinosinusitis with nasal polyps is a condition that lasts longer than 8 weeks.
Chronic sinusitis (CS) and chronic rhinosinusitis (CRS) are conditions that last longer
than eight weeks. The underlying causes of acute sinusitis and acute rhinosinusitis may lead to
chronic sinusitis or chronic rhinosinusitis if the resulting inflammation persists for more than 8
weeks. Chronic rhinosinusitis includes for e, eosinophilic chronic hyperplastic
rhinosinusitis.
Additional subcategories of chronic sinusitis (and chronic rhinosinusitis) e, e.g.,
superantigen-induced eosinophilic chronic sinusitis (e.g., sinusitis induced by exo- and endo-
toxins produced by bacteria such as Staphylococcus aureus); allergic fungal sinusitis (e.g.,
sinusitis induced by fungi such as Aspergil/us or Alternaria); non-allergic fungal eosinophilic
chronic sinusitis; and aspirin-exacerbated eosinophilic chronic sinusitis.
An lL-4R antagonist can be used to treat nasal polyposis in subjects having any of the
disorders described above.
Methods for Improving Nasal Polyp-Associated Parameters
The present invention includes methods for ing one or more nasal polypassociated
parameters in a subject in need thereof, wherein the methods include administering
a pharmaceutical ition comprising an eukin-4 receptor (IL-4R) antagonist to the
subject. For example, an lL-4R or antagonist can reduce endoscopic nasal polyp score
in a patient. A nasal polyp score of 0 indicates the presence of no polyps. A nasal polyp score
of 1 indicates the presence of small polyps in the middle meatus not reaching below the inferior
border of the middle ate. A nasal polyp score of 3 indicates large polyps reaching the
lower border of the inferior turbinate or polyps medial to the middle turbinate. A nasal polyp
score of 4 indicates large polyps causing complete obstruction of the inferior nasal cavity (see
Table 15 below). The maximum score is 8 (4 points per nasal ). Treatment with an lL-4R
antagonist can decrease nasal polyp score by about 1 to about 8 points. For example, treatment
with an lL-4R nist can decrease nasal polyp score by about 1 point or more, by about 2
points or more, or by about 3 points or more. In some embodiments, ent with an lL-4R
antagonist can decrease nasal polyp score by about 1 point, or a fraction f; by 2 points, or
a on f; by 3 points, or a fraction thereof; by 4 points, or a fraction thereof; by 5 points,
or a fraction thereof; by 6 points, or a fraction thereof; by 7 points, or a on thereof; or by 8
points or a fraction thereof. A reduction in nasal polyp score may correlate with an improvement
in one or more other nasal polyp-associated parameters. Such a correlation, however, is not
necessarily observed in all cases.
Other examples of "nasal polyp-associated parameters" e: (a) 22-item SinoNasal
Outcome Test (SNOT-22) score; (b) subject-assessed nasal tion/obstruction, anterior
rhea (runny nose), posterior rhinorrhea (post nasal drip) and loss of sense of smell; (c)
number of nocturnal awakenings; (d) Visual Analog Score (VAS) to assess t-rated
rhinosinusitis symptom severity; (e) five-item Asthma l Questionnaire (ACOS) score, such
as in patients with asthma; (f) Nasal Peak lnspiratory Flow (NPIF); (g) smell test (University of
Pennsylvania Smell Identification Test (UPSIT)); (h) physiological parameters, such as
measured by nasal endoscopy and CT scan; (i) ackay Score; and (j) Three ional
volumetric measurement of the maxillary sinus.
22-ltem Sinonasal Outcome Test 22) Score. According to certain
embodiments, administration of an lL-4R antagonist to a patient results in a decrease from
baseline of 22-item Sinonasal Outcome Test (SNOT-22). The SNOT-22 is a questionnaire to
assess the impact of chronic rhinosinusitis (CRS) on quality of life. The questionnaire measures
items d to sinonasal conditions and surgical treatments. The score ranges from 0 to 110,
and higher scores imply greater impact of CR8 on Health Related Quality of Life (HROoL)
(Hopkins et al 2009, Clin. yngol. 34: 447-454).
The present invention includes therapeutic methods that result in a se in
SNOT-22 score from baseline of at least 1 point at week 4 to week 16 following administration of
the lL-4R antagonist. For example, administration of an lL-4R antagonist will result in a
decrease in SNOT-22 score at week 4, week 6, week 8, week 12, or week 16 following initiation
of treatment. In some embodiments, administration of an lL-4R antagonist to a subject in need
thereof causes a decrease in SNOT-22 score from baseline of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11 13 points, or more at week 4, week 6, week 8 or week 12.
, 12,
Individual and Total Nasal Symptom Score. Subject-assessed symptoms are assayed
by responding to g and evening dual rhinosinusitis symptom questions using a
0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and
3 = severe symptoms), and including the symptoms of congestion and/or obstruction, anterior
rhinorrhea, posterior rhinorrhea, and loss of sense of smell. A measure of night-time
ings can also be tracked. For e, a measure of night-time awakenings can be
assessed according to the following scores based on subject self-assessment: 0: no
symptoms, slept through the night; 1: slept well, but some complaints in the morning; 2: woke
up once because of rhinosinusitis symptoms (including early awakening); 3= woke up several
times because of symptoms (including early ing); 4: bad night, awake most of the night
because of symptoms. Administration of an lL-4R antagonist can result, for example, in a
decrease in average number of nighttime awakenings per night from baseline of at least about
0.10 times per night at week 4 to week 16 ing initiation of treatment with a pharmaceutical
composition sing an anti-lL-4R antagonist. For example, a decrease in frequency of
nighttime awakenings per night from baseline of at least about 0.10 times per night can be
detected at week 4, week 6, week 8, week 12, or week 16 following initiation of treatment.
Administration of an lL-4R antagonist to a subject in need thereof can cause a decrease in
average number of nighttime awakenings per night from baseline by about 0.10 times per night,
0.15 times per night, 0.20 times per night, 0.25 times per night, 0.30 times per night, 0.35 times
per night, 0.40 times per night, 0.45 times per night, 0.50 times per night, 0.55 times per night,
0.60 times per night, 0.65 times per night, 0.70 times per night, 0.75 times per night, 0.80 times
per night, 0.85 times per night, 0.90 times per night, 0.95 times per night, 1.0 time per night, 2.0
times per night, or more at week 4, week 8, week 12, or week 16, for example.
Visual Analog Score (VAS). The VAS is a measure to assess patient-related
rhinosinusitis symptom severity on a scale of 1 to 10. Mild symptoms are indicated by a score of
0 to 3, moderate symptoms are indicated by a VAS score of >3 to 7, and severe symptoms are
indicated by a VAS score of >7 to 10. Administration of an lL-4R antagonist to a subject in need
thereof causes a decrease in VAS score from baseline of about 0.5 point, 1 point, 1.5 , 2
points, 2.5 points, 3 points, 3.5 points, 4 points, or more at week 4, week 6 or week 12. The
decrease in VAS score can be detected as early as week 4, and as late as week 12 or later
following administration of the lL-4R antagonist.
5-ltem Asthma Control Questionnaire (ACQ) Score. The A005 measures both the
adequacy of asthma l and change in asthma control, which occurs either spontaneously
or as a result of treatment. The five questions on the A005 reflect the top-scoring five asthma
symptoms: woken at night by symptoms, wake in the mornings with symptoms, tion of
daily activities, shortness of breath and wheeze. ts respond to the symptom questions on
a 7-point scale (0=no ment, totally controlled; 6: m impairment, severely
uncontrolled).
The present invention includes therapeutic methods which result in a decrease in
A005 score from baseline of at least 0.10 point at week 12 following initiation of treatment with
a pharmaceutical composition comprising an anti-lL-4R antagonist. For e, according to
the present invention, stration of an lL-4R antagonist to a subject in need thereof causes
a decrease in ACQ score from baseline of about 0.10 points, 0.15 points, 0.20 points, 0.25
points, 0.30 points, 0.35 points, 0.40 points, 0.45 points, 0.50 points, 0.55 points, 0.60 points,
0.65 points, 0.70 points, 0.75 points, 0.80 , 0.85 points, or more at week 4, week 6 or
week 12. The decrease in ACQ score can be detected as early as week 4, and as late as week
12 or later following administration of the lL-4R antagonist.
[0047] Nasal Peak atory Flow (NPIF). The Nasal Peak atory Flow (NPIF)
represents a physiologic measure of air flow through both nasal cavities during forced inspiration
and/or expiration expressed in liters per minute. Nasal inspiration correlates most with the
subjective feeling of obstruction and is used to monitor nasal flow. Administration of an lL-4R
antagonist to a subject in need thereof causes an increase in NPIF from baseline by about 0.10
liters per , 0.15 liters per minute, 0.20 liters per minute, 0.25 liters per minute, 0.30 liters
per minute, 0.35 liters per minute, 0.40 liters per minute, 0.45 liters per minute, 0.50 liters per
minute, 0.55 liters per , 0.60 liters per minute, 0.65 liters per minute, 0.70 liters per
minute, 0.75 liters per minute, 0.80 liters per , 0.85 liters per minute, or more at week 4,
week 6 or week 12. The increase in NPIF score can be detected as early as week 4, and as
late as week 12 or later following administration of the lL-4R antagonist.
University of Pennsylvania Smell fication Test (UPSIT). The UPSIT is a method
to quantitatively assess human olfactory function. The test consists of samples of odorants, and
the subject has to describe the odor. The score is based on the number of correct answers.
This test can distinguish patients with a normal sense of smell ("normosmia") from those with
different levels of reduction ("mild, moderate and severe microsmia") or loss mia").
Administration of an lL-4R antagonist to a subject in need thereof causes an increase in UPSIT
score from baseline by about 0.5 points, 1 point, 1.5 , 2 points, 2.5 points, 3 points, 3.5
points or more at week 4, week 6 or week 12. The increase in UPSIT score can be ed as
early as week 4, and as late as week 12 or later following administration of the lL-4R nist.
Physiological parameters. Efficacy of an lL-4R antagonist can be assayed by
measuring the effect of physiological ters, such as within the nasal cavities, such as by
nasal endoscopy or computed tomography (CT) scan.
[0050] Lund-Mackay Score. The Lund-Mackay scoring system is based on localization with
points given for degree of opacification: 0 = normal, 1 = partial opacification, 2 = total
opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid,
sphenoid, and frontal sinus on each side. The eatal complex is graded as 0 = not
occluded, or 2 = occluded ng a maximum score of 12 per side. For patients in whom the
osteomeatal complex (00) is missing (because of a previous surgery) the location of the former
DC is considered and a score is provided, as if the 00 was there. Administration of an lL-4R
antagonist to a subject in need thereof causes a decrease in Lund-Mackay score from baseline
by about 0.10 points, 0.15 points, 0.20 points, 0.25 , 0.30 points, 0.35 , 0.40 ,
0.45 points, 0.50 points, 0.55 points, 0.60 points, 0.65 points, 0.70 points, 0.75 points, 0.80
points, 0.85 points, or more at week 4, week 6 or week 12. The decrease in Lund-Mackay score
can be detected as early as week 4, and as late as week 12 or later following administration of
the lL-4R antagonist.
Three-Dimensional volumetric measurement of maxillary sinus. This value is used to
calculate the volume of air (mL); the volume of mucosa (mL); the percent sinus occupied by
disease; and the thickness of lateral wall in the maxillary sinus. Administration of an lL-4R
antagonist to a subject in need thereof causes an increase in the Three-Dimensional volumetric
measurement.
Quality of Life (QoL) Questionnaires. Various QoL onnaires can be used to
r cy of an lL-4R antagonist, including Form-36 (SF-36) Questionnaire, the
Euroqol-5D (EQ-5D), nasal polyp related resource use questionnaire, and the patient qualitative
self-assessment.
The SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of
health: physical functioning (10 items) social functioning (2 items) role tions due to physical
problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items),
energy/vitality (4 items), pain (2 items), and general health perception (5 items). For each
dimension, item scores are coded, summed, and transformed on a scale from 0 (worst possible
health state measured by the questionnaire) to 100 (best possible health state). Two
standardized summary scores can also be calculated from the SF-36; the physical component
summary (PCS) and the mental health component summary (MOS).
The EQ-5D is a standardized health-related quality of life questionnaire developed by
the EuroQol Group in order to provide a simple, generic measure of health for clinical and
economic appraisal and inter-disease comparisons. EQ-5D, designed for ompletion by
patients, consists of two parts, the EQ-5D ptive system and the EQ VAS. The EQ-5D
descriptive system ses 5 dimensions: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression; and each ion has 3 levels: no m, some problems, severe
problems. The EQ Visual Analogue Scale (VAS) s the respondent’s self-rated health on a
vertical visual analogue scale. The EQ VAS ‘thermometer’ has endpoints of 100 (Best
imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom.
The nasal polyp related resource use questionnaire is a onnaire of health care
resource utilization for nasal polyposis, including specialist visits, emergency care visits, sick
leaves, days off etc.
[0056] Improvement of a nasal polyp-associated parameter, such as a nasal polyp-associated
parameter described above, can be expressed as a percentage. For example, a score can be
improved by 30% or more, by 40% or more, by 50% or more, by 60% or more, by 70% or more,
or by 80% or more.
An "improvement in a nasal polyp-associated parameter" means an increase from
baseline of one or more of NPIF, UPSIT, and/or a decrease from baseline of one or more of
SNOT-22 score, subject-assessed nasal congestion/obstruction, anterior rhinorrhea (runny
nose), posterior rhinorrhea (post nasal drip) and loss of sense of smell; number of nocturnal
awakenings; VAS score; ackay score; and 3D volumetric scores; and ACQ5 score in
patients with asthma. As used herein, the term "baseline," with regard to a nasal polyp-
associated ter, means the cal value of the nasal polyp-associated parameter for a
patient prior to or at the time of administration of a pharmaceutical composition of the present
invenfion.
To determine r a nasal polyp-associated parameter has "improved," the
parameter is quantified at baseline and at a time point after administration of the pharmaceutical
composition of the present invention. For example, a nasal polyp-associated parameter may be
measured at day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11
, day
12, day 14, or at week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11,
week 12, week 13, week 14, week 15, week 16, week 17, week 18, week 19, week 20, week 21,
week 22, week 23, week 24, or longer, after the initial treatment with a pharmaceutical
ition of the present invention. In some embodiments, the ter is measured daily
(e.g., once or twice per day), weekly, biweekly, or monthly. In other embodiments, the
parameter is measured daily and the mean value determined over the course of a month is
compared to baseline.
The difference between the value of the parameter at a particular time point following
initiation of treatment and the value of the parameter at baseline is used to establish whether
there has been an "improvement" in the nasal associated parameter (e.g., an increase or
decrease, as the case may be, depending on the specific parameter being measured).
Interleukin-4 Receptor Antagonists
In one embodiment, a subject in need thereof is administered a therapeutic
composition comprising an interleukin-4 receptor (IL-4R) antagonist. As used herein, an "IL-4R
antagonist" is any agent that binds to or cts with lL-4R and inhibits the normal biological
signaling function of lL-4R when lL-4R is expressed on a cell in vitro or in vivo. miting
examples of ries of lL-4R antagonists include small molecule lL-4R antagonists, peptide-
based lL-4R antagonists (e.g., "peptibody" molecules), and antibodies or n-binding
fragments of antibodies that specifically bind human lL-4R.
[0061] The term "human lL-4R" (hlL-4R), as used herein, is ed to refer to the r
subunit, which is a component of the lL-4 receptors Type | and Type II, as well as the lL-13
receptor system. An lL-4R antagonist, such as an anti-lL-4Roc antibody or antigen-binding
nt thereof, blocks the function of both lL-4 and lL-13 signal transduction.
The term ody", as used herein, is intended to refer to immunoglobulin molecules
comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-
connected by disulfide bonds, as well as multimers thereof (e.g., lgM). Each heavy chain
ses a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain
constant . The heavy chain constant region comprises three domains, CH1, CH2 and CH3.
Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and
a light chain constant region. The light chain constant region comprises one domain (CL1). The
VH and VL regions can be r subdivided into s of hypen/ariability, termed
complementarity determining regions (CDRs), interspersed with regions that are more
consen/ed, termed framework regions (FR). Each VH and VL is composed of three CDRs and
four FRs, arranged from terminus to carboxy-terminus in the following order: FR1, CDR1,
FR2, CDR2, FR3, CDRB, FR4. In some embodiments, the PBS of the anti-Ang-2 antibody (or
antigen-binding portion thereof) may be identical to the human germline sequences, or may be
naturally or artificially modified. An amino acid sus sequence may be defined based on a
side-by-side analysis of two or more CDRs.
The term "antibody," as used herein, also includes antigen-binding nts of full
antibody molecules. The terms "antigen-binding portion" of an antibody, "antigen-binding
fragment" of an antibody, and the like, as used herein, include any naturally occurring,
enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that
specifically binds an antigen to form a complex. Antigen-binding fragments of an antibody may
be derived, e.g., from full antibody molecules using any le standard techniques such as
lytic digestion or recombinant genetic engineering techniques involving the manipulation
and expression of DNA encoding dy variable and optionally constant s. Such DNA
is known and/or is readily ble from, e.g., cial sources, DNA libraries ding,
e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and
manipulated chemically or by using molecular y techniques, for example, to arrange one
or more le and/or constant domains into a suitable uration, or to introduce codons,
create cysteine residues, modify, add or delete amino acids, etc.
Non-limiting examples of antigen-binding fragments e: (i) Fab fragments;
(ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv)
molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid
residues that mimic the hypervariable region of an antibody (e.g., an isolated
complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-
CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single
domain antibodies, domain-deleted dies, chimeric antibodies, CDR-grafted
antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent
nanobodies, nt nanobodies, etc.), small r immunopharmaceuticals (SMIPs),
and shark variable IgNAR domains, are also encompassed within the expression "antigen-
binding fragment," as used herein.
[0065] An antigen-binding fragment of an antibody will typically comprise at least one variable
domain. The variable domain may be of any size or amino acid composition and will generally
se at least one CDR which is adjacent to or in frame with one or more framework
sequences. In antigen-binding fragments having a VH domain associated with a VL domain, the
VH and VL domains may be situated relative to one another in any suitable arrangement. For
example, the variable region may be dimeric and contain VH-VH, VH-VL or VL-VL dimers.
Alternatively, the antigen-binding fragment of an dy may contain a monomeric VH or VL
domain.
In certain embodiments, an antigen-binding fragment of an antibody may contain at
least one variable domain covalently linked to at least one constant domain. Non-limiting,
exemplary configurations of variable and constant domains that may be found within an nbinding
fragment of an antibody include: (i) VH-CHf; (ii) VH-CH2; (iii) VH-CHB; (iv) VH-CHf -CH2; (v)
VH-CH1-CH2-CH3; (vi) -CH3; (vii) VH-CL; (viii)VL-CH1; (ix) VL-CH2; (X) VL-CHS; (xi) VL-CH1-
CH2; (xii) VL-CHf-CH2-CH3; (xiii) VL-CH2-CH3; and (xiv) VL-CL. In any configuration of variable
and constant domains, including any of the exemplary configurations listed above, the variable
and constant domains may be either directly linked to one another or may be linked by a full or
l hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60
or more) amino acids which result in a flexible or semi-flexible e between adjacent variable
and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding
fragment of an antibody may comprise a homo-dimer or hetero-dimer (or other multimer) of any
of the variable and nt domain configurations listed above in non-covalent association with
one another and/or with one or more ric VH or VL domain (e.g., by disulfide bond(s)).
As with full antibody molecules, antigen-binding fragments may be monospecific or
multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody will
typically comprise at least two different variable s, n each variable domain is
capable of specifically binding to a separate antigen or to a different epitope on the same
antigen. Any multispecific antibody format, including the exemplary bispecific dy formats
disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an
anti-lL-4R antibody using routine techniques available in the art.
The nt region of an antibody is important in the ability of an antibody to fix
complement and mediate cell-dependent cytotoxicity. Thus, the isotype of an antibody may be
selected on the basis of whether it is desirable for the antibody to mediate cytotoxicity.
The term "human antibody", as used herein, is intended to include antibodies having
variable and constant regions derived from human germline immunoglobulin sequences. The
human dies featured in the invention may nonetheless include amino acid residues not
encoded by human germline globulin ces (e.g., mutations introduced by random
or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs
and in particular CDRB. However, the term "human antibody", as used herein, is not intended to
e antibodies in which CDR sequences derived from the germline of another ian
species, such as a mouse, have been grafted onto human framework sequences.
The term "recombinant human antibody", as used herein, is intended to include all
human antibodies that are prepared, expressed, d or isolated by recombinant means,
such as antibodies expressed using a recombinant expression vector transfected into a host cell
(described further , antibodies isolated from a recombinant, combinatorial human
antibody library (described further , antibodies isolated from an animal (e.g., a mouse)
that is transgenic for human globulin genes (see e.g., Taylor et al. (1992) Nucl. Acids
Res. 7-6295) or antibodies prepared, expressed, created or isolated by any other means
that involves splicing of human immunoglobulin gene sequences to other DNA sequences.
Such recombinant human antibodies have variable and constant regions derived from human
germline immunoglobulin sequences. In certain embodiments, however, such recombinant
human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for
human lg sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences
of the VH and VL regions of the recombinant antibodies are sequences that, while derived from
and related to human germline VH and VL sequences, may not naturally exist within the human
dy ne repertoire in vivo.
Human antibodies can exist in two forms that are associated with hinge heterogeneity.
In one form, an immunoglobulin molecule comprises a stable four chain construct of
imately 150-160 kDa in which the dimers are held together by an interchain heavy chain
disulfide bond. In a second form, the dimers are not linked via inter-chain disulfide bonds and a
molecule of about 75-80 kDa is formed composed of a ntly d light and heavy chain
(half-antibody). These forms have been extremely difficult to separate, even after affinity
purification.
The frequency of appearance of the second form in various intact lgG isotypes is due
to, but not limited to, structural differences associated with the hinge region isotype of the
antibody. A single amino acid substitution in the hinge region of the human lgG4 hinge can
significantly reduce the appearance of the second form (Angal et al. (1993) Molecular
logy 30:105) to levels typically observed using a human lng hinge. The instant
invention encompasses dies having one or more mutations in the hinge, CH2 or CH3
region which may be desirable, for example, in production, to improve the yield of the desired
antibody form.
An "isolated antibody," as used herein, means an antibody that has been identified and
separated and/or recovered from at least one component of its natural nment. For
example, an antibody that has been separated or removed from at least one component of an
organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced,
is an "isolated antibody." An isolated antibody also includes an antibody in situ within a
recombinant cell. Isolated antibodies are antibodies that have been subjected to at least one
purification or isolation step. According to certain embodiments, an isolated antibody may be
substantially free of other cellular al and/or chemicals.
The term "specifically binds," or the like, means that an antibody or antigen-binding
fragment thereof forms a x with an antigen that is relatively stable under physiologic
conditions. Methods for determining whether an antibody specifically binds to an antigen are
well known in the art and e, for example, equilibrium dialysis, surface n resonance,
and the like. For example, an dy that "specifically binds" lL-4R, as used herein, es
antibodies that bind lL-4R or portion thereof with a KB of less than about 1000 nM, less than
about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less
than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less
than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less
than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than
about 2 nM, less than about 1 nM or less than about 0.5 nM, as measured in a surface plasmon
resonance assay. An isolated antibody that specifically binds human lL-4R may, however, have
cross-reactivity to other antigens, such as lL-4R molecules from other (non-human) species.
The anti-lL-4R antibodies useful for the methods featured herein may include one or
more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions
of the heavy and light chain variable s as compared to the corresponding germline
sequences from which the dies were d. Such mutations can be readily ascertained
by comparing the amino acid sequences disclosed herein to germline sequences available from,
for example, public antibody sequence databases. The present invention includes s
involving the use of antibodies, and antigen-binding fragments thereof, which are derived from
any of the amino acid sequences disclosed , wherein one or more amino acids within one
or more framework and/or CDR regions are mutated to the corresponding residue(s) of the
germline sequence from which the antibody was derived, or to the corresponding residue(s) of
another human ne sequence, or to a consen/ative amino acid substitution of the
ponding germline residue(s) (such sequence changes are referred to herein collectively
as "germline ons"). A person of ordinary skill in the art, ng with the heavy and light
chain variable region sequences disclosed herein, can easily produce numerous antibodies and
antigen-binding fragments which comprise one or more individual ne mutations or
combinations thereof. In n embodiments, all of the framework and/or CDR residues within
the VH and/or VL domains are mutated back to the residues found in the original germline
sequence from which the antibody was derived. In other embodiments, only n residues
are mutated back to the original germline sequence, e.g., only the mutated residues found within
the first 8 amino acids of FRf or within the last 8 amino acids of FR4, or only the mutated
residues found within CDR1,CDR2 or CDRB. In other ments, one or more of the
framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different
germline sequence (i.e., a germline sequence that is different from the germline sequence from
which the antibody was originally d). Furthermore, the antibodies may contain any
combination of two or more germline mutations within the framework and/or CDR regions, e.g.,
wherein certain individual es are mutated to the corresponding residue of a ular
germline sequence while certain other residues that differ from the original germline sequence
are maintained or are mutated to the corresponding residue of a different germline sequence.
Once ed, antibodies and antigen-binding fragments that contain one or more germline
mutations can be easily tested for one or more d property such as, improved binding
specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological
ties (as the case may be), reduced immunogenicity, etc. The use of antibodies and
antigen-binding fragments obtained in this general manner are encompassed within the present
invenfion.
The present invention also includes methods involving the use of anti-lL-4R antibodies
comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences sed
herein having one or more consen/ative substitutions. For example, the present invention
includes the use of anti-lL-4R antibodies having HCVR, LCVR, and/or CDR amino acid
sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. consen/ative amino
acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences
disclosed herein.
[0077] The term "surface plasmon resonance", as used , refers to an optical
phenomenon that allows for the analysis of real-time interactions by detection of tions in
protein concentrations within a biosensor matrix, for example using the BlAcoreTM system
(Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
The term "KD as used herein, is intended to refer to the equilibrium dissociation
constant of a particular dy-antigen ction.
The term "epitope" refers to an antigenic determinant that interacts with a specific
antigen binding site in the variable region of an antibody le known as a paratope. A
single antigen may have more than one epitope. Thus, different antibodies may bind to different
areas on an antigen and may have different biological effects. Epitopes may be either
conformational or linear. A conformational epitope is produced by spatiallyjuxtaposed amino
acids from different segments of the linear polypeptide chain. A linear epitope is one produced
by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope
may include es of saccharides, phosphoryl , or sulfonyl groups on the n.
According to n exemplary embodiments of the present invention, the lL-4R
antagonist is an anti-lL-4Rd antibody, or antigen-binding fragment thereof comprising a heavy
chain variable region (HCVR), light chain variable region (LCVR), and/or complementarity
determining regions (CDRs) sing any of the amino acid sequences of the L-4R
antibodies as set forth in US Patent Nos. 7,608,693 and 7,605,237. In certain exemplary
embodiments, the anti-lL-4Rd antibody or antigen-binding fragment thereof that can be used in
the context of the methods of the t invention comprises the heavy chain complementarity
determining s (HCDRs) of a heavy chain variable region (HCVR) comprising the amino
acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions
) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID
NO:2. According to certain embodiments, the anti-lL-4Rd antibody or antigen-binding fragment
thereof comprises three HCDRs(HCDR1, HCDR2 and HCDR3) and three LCDRs(LCDR1,
LCDR2 and LCDR3), wherein the HCDRf comprises the amino acid sequence of SEQ ID NO:3;
the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the
amino acid sequence of SEQ ID NO:5; the LCDRf comprises the amino acid sequence of SEQ
ID NO:6; the LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and the LCDR3
ses the amino acid sequence of SEQ ID NO:8. In yet other ments, the anti-IL-4R
antibody or antigen-binding fragment thereof comprises an HCVR sing SEQ ID NO:1 and
an LCVR comprising SEQ ID NO:2. According to certain exemplary embodiments, the methods
of the present ion comprise the use of the anti-lL-4Rd dy ed to and known in
the art as dupilumab, or a bioequivalent thereof.
The term “bioequivalent” as used herein, refers to a molecule having similar
bioavaiIabiIity (rate and extent of bility) after administration at the same molar dose and
under similar ions (e.g., same route of administration), such that the effect, with respect to
both efficacy and safety, can be expected to be essentially same as the ator molecule.
Two pharmaceutical compositions comprising an lL-4R nist are bioequivalent if they are
pharmaceutically equivalent, meaning they contain the same amount of active ingredient (e.g.,
lL-4R antagonist), in the same dosage form, for the same route of administration and meeting
the same or comparable standards. Bioequivalence can be determined, for example, by an in
vivo study comparing a pharmacokinetic parameter for the two compositions. Parameters
commonly used in bioequivalence studies include peak plasma concentration (Cmax) and area
under the plasma drug concentration time cun/e (AUG).
Other anti-lL-4Rd antibodies that can be used in the context of the methods of the
present invention include, e.g., the antibody referred to and known in the art as AMG317
(Corren etal., 2010, Am J Respir Crit Care Med, 181(8):788-796), or any of the anti-IL-4Rd
antibodies as set forth in US Patent No. 7,186,809, or US Patent No. 8,092,804.
The anti-lL-4Rd antibodies used in the context of the methods of the present invention
may have pH-dependent binding characteristics. For example, an anti-lL-4Rd antibody for use
in the methods of the present invention may t reduced binding to lL-4Rd at acidic pH as
compared to neutral pH. Alternatively, an L-4Ror antibody of the ion may exhibit
enhanced binding to its antigen at acidic pH as compared to neutral pH. The expression "acidic
pH" includes pH values less than about 6.2, e.g., about 6.0, 5.95, 5,9, 5.85, 5.8, 5.75, 5.7, 5.65,
.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or less. As used herein, the
expression "neutral pH" means a pH of about 7.0 to about 7.4. The expression "neutral pH"
includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
In certain instances, "reduced binding to lL-4Rd at acidic pH as compared to neutral
pH" is expressed in terms of a ratio of the KB value of the antibody binding to lL-4Rd at acidic pH
to the KB value of the antibody g to lL-4Rd at neutral pH (or vice versa). For example, an
dy or antigen-binding fragment thereof may be ed as exhibiting "reduced binding to
lL-4Rd at acidic pH as compared to neutral pH" for es of the present invention if the
antibody or antigen-binding fragment thereof exhibits an acidic/neutral KD ratio of about 3.0 or
greater. In certain exemplary embodiments, the acidic/neutral KD ratio for an antibody or
antigen-binding fragment of the present invention can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0,
6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0,
.0. 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0 or greater.
Antibodies with pH-dependent g characteristics may be obtained, e.g., by
screening a population of dies for d (or enhanced) binding to a particular antigen at
acidic pH as compared to l pH. Additionally, modifications of the antigen-binding domain
at the amino acid level may yield antibodies with pH-dependent characteristics. For example, by
substituting one or more amino acids of an antigen-binding domain (e.g., within a CDR) with a
histidine residue, an antibody with reduced antigen-binding at acidic pH relative to neutral pH
may be obtained. As used herein, the expression "acidic pH" means a pH of 6.0 or less.
Pharmaceutical Compositions
The present invention includes s which include stering an lL-4R
antagonist to a patient, where the lL-4R antagonist is contained within a pharmaceutical
composition. The pharmaceutical compositions featured in the invention are formulated with
suitable carriers, excipients, and other agents that e suitable transfer, delivery, tolerance,
and the like. A multitude of appropriate formulations can be found in the formulary known to all
pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company,
Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies,
waxes, oils, lipids, lipid (cationic or anionic) containing es (such as LIPOFECTINTM), DNA
conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions
carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid
es containing carbowax. See also Powell et al. "Compendium of excipients for parenteral
formulations" PDA (1998) J Pharm Sci Technol 52:238-311.
The dose of antibody administered to a patient may vary depending upon the age and
the size of the patient, ms, conditions, route of administration, and the like. The
preferred dose is typically ated according to body weight or body surface area. Depending
on the severity of the condition, the frequency and the duration of the treatment can be adjusted.
Effective dosages and schedules for administering pharmaceutical compositions comprising
anti-lL-4R antibodies may be determined empirically; for example, patient progress can be
monitored by periodic assessment, and the dose ed accordingly. Moreover, pecies
scaling of dosages can be performed using nown methods in the art (e.g., Mordenti eta/.,
1991 Pharmaceut. Res. 8:1351).
Various delivery systems are known and can be used to administer a pharmaceutical
composition containing an lL-4R antagonist, including encapsulation in mes,
microparticles, apsules, recombinant cells e of expressing the mutant viruses,
receptor mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432).
Methods of administration e, but are not limited to, intradermal, intramuscular,
intraperitoneal, intravenous, subcutaneous, intranasal, al, and oral routes. The
composition may be stered by any convenient route, for example by infusion or bolus
injection, by absorption through lial or mucocutaneous linings (e.g., oral mucosa, rectal
and intestinal mucosa, etc.) and may be administered together with other biologically active
agents.
A pharmaceutical composition can be delivered aneously or intravenously with a
standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery
device readily has applications in delivering a pharmaceutical composition. Such a pen delivery
device, including an jection pen delivery device, can be reusable or disposable. A
reusable pen delivery device generally utilizes a replaceable cartridge that contains a
pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge
has been administered and the cartridge is empty, the empty cartridge can readily be discarded
and replaced with a new cartridge that contains the pharmaceutical composition. The pen
delivery device can then be reused. In a disposable pen ry device, there is no replaceable
cartridge. Rather, the able pen ry device comes prefilled with the pharmaceutical
composition held in a reservoir within the . Once the oir is emptied of the
pharmaceutical composition, the entire device is discarded.
Numerous reusable pen and autoinjector delivery devices have applications in the
subcutaneous delivery of a pharmaceutical composition. Examples include, but are not d
to AUTOPENTM (Owen Mumford, lnc., Woodstock, UK), DlSETRONlCTM pen (Disetronic
Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTM pen,
HUMALIN 70/30TM pen (Eli Lilly and 00., Indianapolis, IN), NOVOPENTM I, II and Ill (Novo
Nordisk, Copenhagen, Denmark), NOVOPEN TM (Novo Nordisk, Copenhagen,
Denmark), BDTM pen (Becton son, Franklin Lakes, NJ), OPTIPENTM, OPTIPEN PROT'V',
N STARLETTM, and OPTICLIKTM (sanofi-aventis, Frankfurt, Germany), to name only a
few. Examples of disposable pen delivery devices having applications in subcutaneous delivery
of a pharmaceutical composition include, but are not limited to the SOLOSTARTM pen (sanofi-
aventis), the NTM (Novo Nordisk), and the KWIKPENTM (Eli Lilly), the ICKTM
Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTM (Haselmeier, Stuttgart, y),
the EPIPEN (Dey, LP), and the HUMIRATM Pen (Abbott Labs, Abbott Park IL), to name only a
few.
For direct administration to the sinuses, the pharmaceutical compositions containing lL-
4R antagonists may be administered using, e.g., a microcatheter (e.g., an endoscope and
microcatheter), an aerosolizer, a powder dispenser, a nebulizer or an r.
In certain situations, the pharmaceutical composition can be delivered in a controlled
release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, 1987,
CRC Crit. Ref. Biomed. Eng. 14201). In another embodiment, polymeric als can be used;
see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres.,
Boca Raton, a. In yet another embodiment, a controlled release system can be placed in
proximity of the compositions target, thus requiring only a fraction of the systemic dose (see,
e.g., Goodson, 1984, in Medical Applications of Controlled Release, supra, vol. 2, pp. 8).
Other controlled release systems are discussed in the review by Langer, 1990, Science
27-1533.
The injectable preparations may include dosage forms for intravenous, subcutaneous,
intracutaneous and intramuscular ions, drip infusions, etc. These injectable preparations
may be prepared by known methods. For example, the injectable preparations may be
prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above
in a sterile aqueous medium or an oily medium conventionally used for injections. As the
aqueous medium for ions, there are, for example, physiological saline, an isotonic solution
containing glucose and other auxiliary agents, etc., which may be used in combination with an
appropriate solubilizing agent such as an l (e.g., ethanol), a polyalcohol (e.g., propylene
glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50
(polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there
are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a
lizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is
ably filled in an appropriate ampoule.
Advantageously, the pharmaceutical compositions for oral or parenteral use described
above are prepared into dosage forms in a unit dose suited to fit a dose of the active
ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules,
injections (ampoules), suppositories, etc.
Dosage
The amount of lL-4R antagonist (e.g., anti-lL-4R antibody, or antigen binding fragment
thereof) administered to a subject according to the s featured herein is generally a
eutically effective amount. As used herein, the phrase "therapeutically effective "
means a dose of lL-4R nist that results in a detectable improvement in one or more
ms ated with nasal polyps, or a dose of lL-4R antagonist that inhibits, prevents,
lessens, or delays the progression of nasal polyps or a condition associated with nasal polyps.
In the case of an anti-lL-4R antibody, a therapeutically effective amount can be from about 0.05
mg to about 600 mg, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0
mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70
mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg,
about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about
200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260
mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg,
about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about
390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450
mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg,
about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about
580 mg, about 590 mg, or about 600 mg, of the anti-lL-4R antibody or antigen binding fragment.
The amount of lL-4R nist ned within the individual doses may be
sed in terms of milligrams of antibody per kilogram of patient body weight (i.e., mg/kg).
For example, the lL-4R antagonist may be administered to a patient at a dose of about 0.0001 to
about 10 mg/kg of patient body weight.
Combination ies
[0097] The methods, according to certain embodiments, include administering to the subject
one or more additional therapeutic agents in combination with the lL-4R antagonist. As used
herein, the expression "in combination with" means that the additional therapeutic agents are
administered before, after, or concurrent with the pharmaceutical composition comprising the IL-
4R antagonist. For example, when administered "before" the pharmaceutical composition
comprising the lL-4R nist, the additional therapeutic agent may be administered about 72
hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about
hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30
minutes, about 15 minutes or about 10 minutes prior to the administration of the ceutical
composition sing the lL-4R antagonist. When administered "after" the pharmaceutical
composition comprising the lL-4R antagonist, the additional therapeutic agent may be
administered about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2
hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24
hours, about 36 hours, about 48 hours, about 60 hours or about 72 hours after the
administration of the ceutical composition sing the lL-4R antagonist.
Administration "concurrent" with the ceutical composition comprising the lL-4R
antagonist means that the additional eutic agent is administered to the subject in a
separate dosage form within less than 5 minutes (before, after, or at the same time) of
administration of the pharmaceutical composition comprising the lL-4R antagonist, or
administered to the subject as a single combined dosage formulation comprising both the
additional therapeutic agent and the lL-4R antagonist.
The additional therapeutic agent may be, e.g., another lL-4R antagonist, an lL-1
antagonist (including, e.g., an lL-1 antagonist as set forth in US Patent No. 6,927,044), an lL-6
antagonist, an lL-6R antagonist (including, e.g., an anti-lL-6R antibody as set forth in US Patent
No. 7,582,298), an lL-13 antagonist, a TNF antagonist, an lL-8 antagonist, an lL-9 antagonist,
an lL-17 antagonist, an lL-5 antagonist, an lgE nist, a CD48 antagonist, an antibiotic
(e.g., doxycycline), an anti-fungal agent, a leukotriene, an antihistamine, an d-adrenergic
decongestant, a tic, an NSAID, a long-acting beta2 agonist (e.g., salmeterol or
formoterol), a short-acting beta2 agonist, a steroid (e.g., an oral steroid), a corticosteroid, such
as an intranasal corticosteroid (e.g., mometasone furoate (MFNS; e.g., Nasonex®)), or an
inhaled corticosteroid (e.g., fluticasone or budesonide), an allergen immunotherapy, or
combinations thereof. For example, in certain ments, the pharmaceutical composition
comprising an lL-4R antagonist is administered in combination with a combination comprising a
cting beta2 agonist and an inhaled corticosteroid (e.g., fluticasone + salmeterol [e.g.,
Advair® (GlaxoSmithKline)]; or budesonide + formoterol [e.g., ort® (Astra Zeneca)]).
In some embodiments, the lL-4R antagonist is administered after a subject receives
surgery to treat nasal polyposis.
Administration Regimens
According to certain ments, multiple doses of an lL-4R antagonist may be
administered to a subject over a defined time course. The methods include, for example,
sequentially administering to a subject multiple doses of an lL-4R antagonist. As used herein,
"sequentially stering" means that each dose of lL-4R antagonist is administered to the
subject at a different point in time, e.g., on different days separated by a ermined inten/al
(e.g., hours, days, weeks or months). The present invention includes methods which comprise
sequentially administering to the patient a single initial dose of an lL-4R antagonist, followed by
one or more secondary doses of the lL-4R antagonist, and optionally followed by one or more
ry doses of the lL-4R antagonist.
[00101] The terms "initial dose," "secondary doses," and "tertiary " refer to the temporal
ce of administration of the lL-4R antagonist. Thus, the "initial dose" is the dose which is
administered at the beginning of the ent regimen (also referred to as the "baseline ;
the "secondary doses" are the doses which are administered after the initial dose; and the
ary doses" are the doses which are administered after the secondary doses. The initial,
secondary, and tertiary doses may all contain the same amount of lL-4R antagonist, but will
generally differ from one another in terms of frequency of administration. In certain
embodiments, however, the amount of lL-4R antagonist contained in the initial, secondary
and/or tertiary doses will vary from one another (e.g., adjusted up or down as appropriate)
during the course of treatment.
[00102] In one exemplary embodiment, each secondary and/or ry dose is administered 1
to 14 (e.g., 1, 11/2, 2, 21/2, 3, 31/2, 4, 41/2, 5, 51/2, 6, 61/2, 7, 71/2, 8, 81/2, 9, 91/2, 10, 101/2, 11,111/2, 12,
121/2, 13, 131/2, 14, 141/2, or more) weeks after the immediately preceding dose. The phrase "the
immediately preceding dose," as used herein, means, in a sequence of multiple administrations,
the dose of lL-4R antagonist which is administered to a patient prior to the stration of the
very next dose in the sequence with no inten/ening doses.
These methods may include administering to a patient any number of secondary and/or
tertiary doses of an lL-4R nist. For example, in certain embodiments, only a single
secondary dose is administered to the t. In other embodiments, two or more (e.g., 2, 3, 4,
, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, in certain
embodiments, only a single tertiary dose is administered to the patient. In other embodiments,
two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) ry doses are administered to the patient.
In embodiments involving multiple secondary doses, each secondary dose may be
administered at the same frequency as the other secondary doses. For example, each
secondary dose may be administered to the patient 1 to 2 weeks after the immediately
preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose
may be administered at the same frequency as the other tertiary doses. For example, each
tertiary dose may be administered to the patient 2 to 4 weeks after the ately preceding
dose. Alternatively, the frequency at which the secondary and/or tertiary doses are
administered to a patient can vary over the course of the treatment regimen. The frequency of
administration may also be ed during the course of ent by a ian depending on
the needs of the individual patient following clinical examination.
In certain embodiments, the initial dose (e.g., a “loading dose”) is higher than either or
both of the secondary and tertiary doses. For example, the initial dose can be a loading dose,
which is 1.5x, 2x, 2.5x, 3x or more greater than the secondary dose.
Treatment Populations
The methods ed in the present invention including administering to a subject in
need thereof a therapeutic composition comprising an lL-4R antagonist. As used , the
expression "a subject in need thereof" means a human or non-human animal that exhibits one
or more symptoms or indication of nasal polyposis, or who has been sed with nasal
polyposis, or c ms of sinusitis. For example, a subject in need f has bilateral
nasal polyps, and a nasal polyp score of at least 5 out of a maximum of 8 for both nostrils, with
at least a score of 2 for each nostril. In certain embodiments, the polyps are in the middle
meatus. In certain ments, the presence of nasal polyps is confirmed by endoscopy. In
some embodiments, the subject also has bilateral mucosal disease, which is confirmed by a
method such as CT scan. As used herein “bilateral l disease” is an infection of the
mucous lining of the sinus cavities, e.g., the ary sinus cavities. In some embodiments,
nasal polyposis (e.g., a nasal polyp score of at least 5 out of a maximum of 8 for both nostrils,
with at least a score of 2 for each nostril) persists even after a treatment regimen of inhaled
corticosteroids (INCS), such as where the INCS was administered for at least 6 weeks, at least
7 weeks, at least 8 weeks, or longer.
In certain ments, a subject in need thereof has anterior and/or posterior
mucopurulent drainage, nasal obstruction, and a decreased sense of smell. In certain
ments, a subject in need thereof has had symptoms of nasal polyposis for 6 weeks, 7
weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks or more. In yet other embodiments,
the subject has received a previous treatment, such as with an intranasal corticosteroid (e.g.,
MFNS), for at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8
weeks, at least 9 weeks, at least 10 weeks or longer, prior to ing treatment with an lL-4R
antagonist. In some embodiments the subject will continue to receive the INCS while receiving
ent with the lL-4R antagonist. In other embodiments, the subject stops receiving the
INCS before receiving treatment with the lL-4R antagonist, or the subject stops ing
ent with the INCS if administration with the lL-4R antagonist is effective to treat the nasal
sis. In some embodiments, the subject tapers the dose of the INCS before stopping
treatment completely.
A subject in need thereof may further have been diagnosed with nasal polyposis on the
basis of one or more of the following: (a) 22—item sal e Test (SNOT-22) score;
(b) subject-assessed nasal congestion/obstruction, anterior rhinorrhea, posterior rhinorrhea and
loss of sense of smell; (c) number of nocturnal awakenings; (d) Visual Analog Score (VAS) to
assess patient-rated rhinosinusitis m severity; (e) five-item Asthma Control Questionnaire
(ACQ5) score in patients with asthma; (f) Nasal Peak lnspiratory Flow (NPIF); (g) smell test
rsity of Pennsylvania Smell Identification Test (UPSIT); (h) physiological parameters, such
as measured by nasal endoscopy and CT scan; (i) Lund-Mackay Score; and (k) Three
Dimensional volumetric measurement of the maxillary sinus.
For example, in certain embodiments, a “subject in need thereof” is a human t
with chronic symptoms of sinusitis, which are the presence of at least two of the following
symptoms: nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal
drip); facial pain/pressure; and reduction or loss of smell.
In certain embodiments, a "subject in need thereof" is a human patient with a SNOT-22
score of greater than about 7, greater than about 10, greater than about 15, greater than about
, greater than about 25, greater than about 30, greater than about 35, greater than about 40,
greater than about 45, or greater than about 50. A "subject in need thereof" may also be a
human patient who exhibits a Lund-Mackay score of greater than about 4, greater than about 5,
greater than about 6, greater than about 7, greater than about 8, greater than about 9, greater
than about 10, greater than about 11, greater than about 12, or greater than about 13.
In a related ment, a "subject in need thereof" may be a subject who, prior to
ing an lL-4R antagonist, has been prescribed or is currently taking another medication, “a
background therapy.” The background therapy can be, for example, an asal corticosteroid
(INCS, or 108), such as sone furoate nasal spray (MFNS; Nasonex®). In some
embodiments, a “subject in need thereof” is an asthma patient who prior to receiving an lL-4R
antagonist, has been prescribed or is currently taking an INCS in combination with a long-acting
beta2-adronergic antagonist (LABA). Examples of lNCS/LABA therapies e
fluticasone/salmeterol combination y and budesonide/formoterol ation therapy. In
some embodiments, the background therapy is a nasal saline, a topical decongestant, a topical
anesthetic, a leukotriene nist or a systemic antihistamine. In some embodiments, the
“subject in need thereof” continues the background therapy after the subject receives the lL-4R
nist, and in other ments, the subject in need thereof stops receiving the
background therapy (e.g., at once or gradually) before receiving the lL-4R antagonist.
EXAMPLES
The following examples are put forth so as to e those of ordinary skill in the art
with a complete sure and description of how to make and use the methods and
compositions featured in the invention, and are not intended to limit the scope of what the
ors regard as their invention. Efforts have been made to ensure accuracy with respect to
numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations
should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular
weight is e molecular weight, temperature is in degrees Centigrade, and pressure is at or
near atmospheric.
Example 1: Clinical Trial of Subcutaneously Administered Anti-IL-4R Antibody (mAb1) In
Patients with Persistent Moderate-to-Severe Eosinophilic Asthma, Including Asthma
Patients with Chronic Hyperplastic Eosinophilic Sinusitis
A. Study Objectives and ew
A randomized, o-controlled, double-blind, parallel group study was conducted
with once-a-week subcutaneous administration of either 300 mg dupilumab (“mAb1”) or placebo
for 12 weeks to patients with persistent moderate-to-severe eosinophilic asthma who were
partially controlled/uncontrolled by inhaled corticosteroid (ICS) and long-acting beta2 agonist
(LABA) y. Dupilumab is an anti-lL-4R antibody having a heavy chain le region of
SEQ ID NO:1, and a light chain variable region of SEQ ID NO:2. Dupilumab is described in US
7,608,693.
The primary objective of the study was to investigate the effects of mAb1 administered
subcutaneously once weekly for 12 weeks as compared to placebo on ng the incidence of
asthma exacerbations in patients with persistent moderate-to-severe eosinophilic asthma. The
secondary objectives of the study were to assess the safety and bility of mAb1
administered subcutaneously once weekly for 12 weeks in patients with persistent moderate to
severe eosinophilic asthma, and to assess mAb1 serum concentrations following once weekly
subcutaneous dosing for 12 weeks in patients with persistent te to severe eosinophilic
asthma.
] Prior to screening, patients were required to be on a stable dose of any of the following
doses and formulations of lCS/LABA combination therapy (also called “background therapy”) for
at least 1 month:
Fluticasone/salmeterol combination therapy
- Advair® Diskus — dry powder inhaler (DPI): 250/50 ug BID or 500/50 ug BID; or
- Advair® HFA — d dose inhaler (MDI): 230/42 ug BID or 460/42 ug BID; or
Budesonide/formoterol combination therapy (Symbicort® 160/9 ug BID or 320/9 ug BID); or
Mometasone/formoterol combination therapy (Dulera® 200/10 ug BID or 400/10 ug BID)
] Patients who were on budesonide/formoterol or mometasone/formoterol were switched
to an equivalent dose of fluticasone/salmeterol at randomization (Day 1) and patients who had
been on fluticasone/salmeterol remained on the same as background therapy.
Patients who ied the inclusion and exclusion criteria (see below) were randomized
to one of the following treatments: 300 mg of mAb1 administered subcutaneously once weekly
for 12 weeks; or placebo administered subcutaneously once weekly for 12 weeks.
[00118] The study comprised a 2-week screening period, a 12-week treatment period
comprising a 4-week ound therapy stable phase and an 8-week background therapy
withdrawal phase post-randomization, ed by an 8-week post-treatment follow-up period.
Algorithm for background therapy (ICS/LABA) withdrawal:
Patients remained on BID fluticasone/salmeterol background therapy for 4 weeks after
starting add-on therapy or treatment of 300 mg mAb1 (or placebo). At 4 weeks post-
randomization, patients were switched from the BID fluticasone/salmeterol combination therapy
to an equivalent ICS dose of fluticasone erapy (comprising either Flovent® Diskus — DPI
formulation of 250ug or 500 ug BID; or Flovent® HFA — MDI formulation of 220 ug or 440 ug
BID). The LABA component (i.e., salmeterol) was discontinued. At subsequent visits, beginning
with week 6, the fluticasone dose was d by imately 50%, provided the patient did
not meet any of the criteria for an asthma exacerbation (as defined below). If no asthma
exacerbations occurred, the ICS withdrawal ded according to the following dosing
schedule:
ound therapy ound therapy withdrawal phase
stable phase
Week 4 Week 6 Week 7 Week 8 Week 9
Fluticasone/salmeterol Fluticasone 100 pg 50 ug BID 0 ug BID 0 ug
(DPI): 250/50 pg BID (DPI): 250 ug BID BID BID
Fluticasone/salmeterol Fluticasone 250 pg 100 pg 50 ug BID 0 ug
(DPI): 500/50 pg BID (DPI): 500 ug BID BID BID BID
Fluticasone/salmeterol Fluticasone 110 pg 44 ug BID 0 ug BID 0 ug
(MDI): 230/42 ug BID (MDI): 220 ug BID BID
Fluticasone/salmeterol Fluticasone 220 pg 110 pg 44 ug BID 0 ug
(MDI): 460/42 ug BID (MDI): 440 ug BID BID BID
Upon completing 12 weeks of treatment with investigational product (or after early
discontinuation), patients were placed on their original dose of fluticasone/salmeterol,
budesonide/formoterol, or mometasone/formoterol (dose at study entry) and albuterol or
levalbuterol as-needed to control their symptoms for an additional 8 weeks off study medication
before a final safety evaluation.
A schematic of the study protocol is provided in Figure 1.
Adult patients were included in the study based on the ing criteria: (1) physician’s
diagnosis of tent asthma for at least 2 12 months based on the Global Initiative for Asthma
(GINA) 2009 Guidelines, whose y inflammation is likely to be eosinophilic; and (2) whose
asthma is partially controlled or uncontrolled in d corticosteroids/long acting gonists
combination therapy according to the following ia: (i) stable dose of either
fluticasone/salmeterol combination therapy (DPI formulation: 250/50 pg BID or 500/50 pg BID or
MDI formulation: 230/42 pg BID or 460/42 pg BID), or budesonide/formoterol combination
therapy (160/9 pg BID or 320/9 pg BID), or sone/formoterol combination therapy
(200/10 pg BID or 400/10 pg BID) for at least 1 month prior to screening; (ii) blood eosinophils 2
300 cells/pl or sputum eosinophils 2 3% during the screening phase; (iii) Juniper asthma control
questionnaire stion version, ACQ) score of 2 1.5 and s 3.0 at screening; (iv) FEV1 2 50%
predicted normal during the screening phase (3 attempts maximum) and on the ization
day prior to the first dose (3 attempts maximum); (v) has had within the 2 years prior to
ing either treatment with one or more systemic (oral and/or parenteral) steroid bursts for
worsening asthma or in-patient hospitalization or an emergency care visit for worsening asthma;
and (vi) documented history of reversibility within 12 months of screening that meets the
criterion — at least 12% and 200 mL in FEV1 after 200 pg to 400 pg (2 to 4 tions) of
albuterol during the screening phase (3 attempts maximum), or documented history of a positive
methacholine challenge (PD20 methacholine S 8 mg) within 12 months prior to screening.
Patients with moderate-to-severe asthma that is partially controlled or uncontrolled with
moderate to high doses of combination therapy with inhaled corticosteroids and long-acting beta
agonists (ADVAIR®, SYMBICORT® or DULERA®) and with blood eosinophils r than or
equal to 300 cells per microliter, or sputum eosinophils greater than or equal to 3% during the
screening phase, were included in the study.
Patients who met all the inclusion criteria were screened for the following exclusion
criteria: (1) patients less than 18 years of age or greater than 65 years of age; (2) clinically
relevant abnormal laboratory values suggesting an unknown disease and requiring further
evaluation; (3) chronic ctive ary disease (COPD) and/or other lung diseases
ing ary function tests; (4) patients requiring beta-adrenergic receptor blockers for
any reason; (5) current smoker or cessation of smoking within the 6 months prior to screening;
(6) previous smoking with a smoking history > 10 tte pack-years; (7) in-patient
hospitalization or emergency care visit due to asthma exacerbation in the 2 months prior to
screening; (8) plans to begin allergen immunotherapy within the study period; (9) exposure to
another investigative antibody within a time period prior to screening that is less than 5 half-lives
of the antibody but not less than 30 days, or if the half life of the antibody is not known, then a
time period prior to screening that is at least 6 months; (10) previous enrollment into the current
study; (11) patient was the igator, his/her family member or an ee at the
investigational site; (12) known or suspected non-compliance, alcohol or drug abuse; (13)
inability to follow the procedures of the study (e.g., due to language problems or psychological
disorders); (14) reversal of sleep pattern (e.g., night shift worker); (15) treatment with drugs
known to prolong QTc inten/al; (16) concomitant severe disease(s) for which the use of ICS
(e.g., active or inactive pulmonary tuberculosis) or LABA (e.g., diabetes, cardiovascular
diseases, hypertension, hyroidism, thyrotoxicosis, etc) are contra-indicated; (17) use of
injectable glucocorticosteroids or oral systemic glucocorticosteroids within 2 months prior to
screening or more than 3 courses within the 6 months prior to screening; (18) pre-treatment with
variable doses of ICS, either alone or in combination with a non-steroidal controller (other than
fluticasone/salmeterol combination therapy, budesonide/formoterol combination therapy, or
mometasone/formoterol combination therapy); (19) ts receiving prohibited concomitant
medications (listed below); (20) known allergy to doxycycline or d compounds; (21)
pregnancy or intention to become pregnant during the course of the study, breast feeding or
unwillingness to use an effective method of contraception; and (22) recent history of a parasitic
infection or travel to a parasitic endemic area within 6 months prior to ing.
Patients remained on a constant dose of the background asthma therapy for the first
four weeks of the study after which the dose of background therapy was reduced gradually.
First, the long-acting beta agonist component of the background therapy was withdrawn at week
4, and then the inhaled corticosteroid dose was reduced by half every 2 weeks until week 12.
Patients ued on study treatment until the end of the study or until they were withdrawn due
to an asthma exacerbation or for any other .
B. Study Treatments
igational Product: Sterile mAb1 150 mg/mL solution for SC ion was provided
in a 5 mL glass vial. Each vial contained a withdrawable volume of 2 mL. A 300 mg dose was
administered subcutaneously at the study site once weekly in the g for 12 weeks.
Placebo: Sterile placebo for SC injection was ed in an identically matched 5 mL glass vial.
Each vial ned a awable volume of 2 mL. Placebo was administered subcutaneously
at the study site once weekly in the morning for 12 weeks.
[00126] The following concomitant medications were not allowed during the duration of the
study: any other inhaled steroid other than fluticasone/salmeterol combination y or
fluticasone administered per the protocol (or budesonide/formoterol or mometasone/formoterol
during the screening period); systemic or ocular steroids; LABAs other than the salmeterol
component of the fluticasone/salmeterol combination therapy administered per the protocol; any
other ICS/LABA combination products other than those given above; any inhaled anti-
cholinergic agents (e.g., opium bromide or tiotropium); methylxanthines (theophylline,
aminophyllines); cromones; anti-lgE therapy; |ipoxygenase inhibitors; and leukotriene receptor
antagonists or leukotriene synthesis inhibitors.
C. Efficacy of treatment
The primary nt of this study was the occurrence of an exacerbation of asthma as
defined by any of the ing: (1) a 30% or greater reduction from baseline in morning peak
expiratory flow (PEF) on two consecutive days; or (2) six or more additional reliever puffs of
albuterol or levalbuterol in a 24 hour period (compared to baseline) on 2 utive days; or (3)
deterioration of , as determined by the Investigator, requiring: (a) systemic (oral and/or
eral) steroid treatment, or (b) an increase in ICS 24 times the last dose received prior to
discontinuation from the study, or (c) alization.
[00128] Secondary endpoints of the study included mean changes from baseline of the
following parameters: (1) Forced expiratory volume in 1 second (FEV1) in liters measured at
every visit; (2) Morning and evening peak expiratory flow rate (AM PEF and PM PEF) in
/minute measured daily; (3) Daily Albuterol/Levalbuterol use in inhalations/day; (4) Five-
item Asthma Control Questionnaire (ACQ5) score at every visit; and (5) Nighttime awakenings
(no. of times per night) measured daily and (6) a m Sino-Nasal Outcome Test (SNOT-22),
evaluated at baseline and end of ent (at Week 12), to assess upper ainNay symptoms.
Secondary endpoints also included proportion of patients with a composite asthma event
defined by a 30% or greater reduction from baseline in morning PEF on two consecutive days
together with 2 6 additional reliever puffs of rol or levalbuterol in a 24-hour period
red to baseline) on 2 utive days. PEF, ACQS, asthma symptoms scores,
nocturnal awakenings, and reliever medication use were captured in an electronic daily diary.
Mean daily nocturnal awakenings, ranging from 0-10, were averaged from the previous 7 days.
Morning and evening asthma m scores consisted of a non-validated patient-reported
outcome assessed on a 5-point Likert-type scale, with higher scores indicating worse outcomes
(Table 2). Patients recorded overall symptom scores twice a day prior to measuring PEF. Data
were described as the average for the 7 days prior to the specified time point.
Table 2: Asthma Symptom Score Assessment
A) Morning symptom score:
0 = No asthma symptoms, slept through the night
1 = Slept well, but some complaints in the morning. No ime awakenings
2 = Woke up once because of asthma (including early awakening)
3 = Woke up several times because of asthma ding early awakening)
4 = Bad night, awake most of the night because of asthma
B) Evening symptom score:
0 = Very well, no asthma symptoms
1 = One episode of wheezing, cough, or breathlessness
2 = More than one episode of wheezing, cough, or breathlessness without
interference of normal activities
3 = Wheezing, cough, or breathlessness most of the day, which interfered to some
extent with normal activities
4 = Asthma very bad. Unable to carry out daily activities as usual
D. Adverse Events Monitoring
Safety was assessed throughout the study by ring Adverse Events and Serious
Adverse Events.
An Adverse Event (AE) is any untoward medical occurrence in a subject or clinical
investigation subject administered a pharmaceutical product. An AE can, therefore, be any
unfavorable and unintended sign (including al laboratory finding), symptom, or e
ally associated with the use of a medicinal product, whether or not considered related to
the medicinal (investigational) product. AEs also include: any worsening (i.e., any clinically
icant change in frequency and/or ity) of a pre-existing condition that is temporally
associated with the use of the study drug; abnormal laboratory findings considered by the
Investigator to be clinically significant; and any untoward medical occurrence.
A Serious e Event (SAE) is any untoward medical occurrence that at any dose
results in death; is life-threatening; requires ient hospitalization or prolongation of existing
hospitalization; results in persistent or significant disability/ incapacity; is a congenital anomaly/
birth defect; or is an important medical event.
E. tical methods
[00132] For the primary analysis of proportion of patients experiencing an asthma exacerbation,
a logistic regression model was used to compare SAR group with o. The model included
terms for treatment and stratification factor (prior lCS/LABA combination therapy dose). The
primary analysis was performed based on modified -to-treat (mlTT) population which
included all randomized patients who received at least one dose of mAb1. A stratified chi-
square test was also used to corroborate the primary analysis.
For secondary efficacy endpoints except SNOT-22, the change from baseline was
ed using a mixed-effect model with repeated measures (MMRM) approach. The model
included change from baseline values up to week 12 as response variables, and factors (fixed
effects) for treatment, fication factor, visit, treatment-by-visit interaction, baseline value, and
baseline-by-visit interaction. Statistical inferences on treatment comparisons for the change from
ne at week 12 were derived from the mixed-effect model. Change from ne in SNOT-
22 was ed using an analysis of covariance (ANCOVA), with end of treatment
measurements used to impute missing data. Pharmacodynamic effects were evaluated using
MMRM models in a post hocfashion. No ments were made for multiplicity, since there
was only one primary nt and analysis. Safety variables including AEs, laboratory
parameter, vital signs, ECG, clinical laboratory observations and physical examinations were
ized using descriptive statistics.
Demographic and clinical characteristics were summarized using descriptive
characteristics. Plots of secondary and pharmacodynamic variables are presented as mean
change from baseline over time with standard error. Comparison of treatment effects from the
MMBM analyses are based on least square mean change (95% ence inten/als [Cl]) from
baseline at Week 12.
F. Results
The results obsen/ed with all 104 ized patients (from 491 screened) who either
completed or discontinued the treatment phase of the study are summarized below. All
randomized patients were exposed to study treatment and included in the mlTT tion.
Baseline characteristics were r between groups. The demographic and clinical
characteristics were also similar between the two groups (Table 3). As noted above, patients
were treated either with 300 mg subcutaneous mAb1 once a week, or with placebo. The study
treatment period was completed by 86.5% and 67.3% of the mAb1 and placebo patients,
respectively. The most common cause of tinuation was lack of efficacy, which was more
frequent with placebo (21.2%) than mAb1 (1.9%).
Table 3. Baseline Demographic and Clinical Characteristics of Treatment Groups.*
Variable Placebo mAb1 300 mg
(N : 52) (N : 52)
Age (yr) 41.6 i 13.1 37.8 i 13.2
Male sex, no. (%) 26 (50.0) 26 (50.0)
Race or ethnic group, no. (%)
White 38 (73.1) 45 (86.5)
Black or African American 9 (17.3) 5 (9.6)
Asian 3 (5.8) 1 (1.9)
Other 2 (3.8) 1 (1.9)
Body mass index
Mean (kg/m2) 31.6 i 7.0 31.3 i 8 0
2 30, no. (%) 25 (48.1) 24 (46.2)
Duration of asthma (yr) 26.9 :r 14.8 24.2 :r 12.6
Number of asthma exacerbations in prior 2 years 1.4 :r 1.3 1.4 :r 1.0
Prior lCS/LABA combination therapy dose, no. (%)
High Dose 41 (78.8) 42 (80.8)
Low Dose 11 (21.2) 10 (19.2)
Blood eosinophils (x10'/|) 0.47 i 0.21 0.55 i 0.19
FEV, (l) 2.54 i 0.66 2.47 i 0.65
FEV, (% of ted value) 72.0 :r 12.7 72.0 :r 12.6
PEF (l/min)
Morning 406.9 i 110.7 393.0 i 101.1
Variable Placebo mAb1 300 mg
(N : 52) (N : 52)
Evening 416.6 1r 116.8 414.6 1r 102.3
ACQ5 score 2.1 :r 0.5 2.1 :r 0.5
Asthma symptom score
Morning 0.73 i 0.63 0.75 i 0.81
Evening 1.12 1r 0.73 0.92 1r 0.71
Nocturnal ings per day 0.21 :r 0.50 0.44 :r 0.80
SNOT-22 26.2 1r 15.6 30.9 1r 14.8
Inhalations of albuterol or levalbuterol/24-hour period 2.0 :r 1.8 2.2 :r 2.4
FeNO (ppb) 35.0 1r 27.1 37.6 1r 28.1
TARC (pg/ml) 470.5 1r 204.7 496.1 1r 342.4
Eotaxin-3 (pg/ml) 117.3 i 349.2 75.4 i 44.0
lgE (lU/ml) 694.7 1r 1837.8 657.7 1r 1482.3
*Plus—minus values are means i SD, except as otherwise noted. ACQ5 denotes the Asthma
Control Questionnaire (5 question version), FeNO fraction of d nitric oxide, FEV, forced
expiratory volume in 1 second, IgE immunoglobulin E, PEF peak expiratory volume, SNOT-22
the 22-item Sinonasal Outcome Test,
and TARC thymus and tion regulated chemokine.
(i) Primary Efficacy Endpoint
The incidence of asthma exacerbations in the placebo and mAb1 treatment groups is
presented in Table 4.
Table 4. Incidence of Asthma Exacerbations in mlTT population
Placebo (N=52) mAb1 (N=52)
Patients With No Asthma
29 ) 49 (94.2%)
Exacerbations
Patients With Asthma Exacerbations 23 (44.2%) 3 (5.8%)
Odds Ratio vs Placebo (95% Cl) -- 0.077 (0.021, 0.279)
There were a total of 26 asthma exacerbations during the treatment period, and no
patients were hospitalized for asthma bations. There were 23 patients (44.2%) who
experienced an asthma exacerbation in the placebo group, whereas only 3 patients (5.8%)
experienced an asthma exacerbation in the mAb1 treatment group. The odds ratio is 0.077 (p
<0.0001) and the relative risk reduction is approximately 87%.
Out of the 26 asthma bations experienced during this study, 9 were considered
severe as demonstrated by a need for immediate inten/ention in the form of treatment with either
ic corticosteroids or with inhaled osteroids at 4 or more times the dose taken prior to
the event. A y of the incidence of severe asthma exacerbations is presented in Table 5.
Table 5. Incidence of Severe Asthma Exacerbations in mlTT population
Placebo (N=52) mAb1 (N=52)
Patients With No Asthma Exacerbations 29 (55.8%) 49 (94.2%)
Patients WIth Severe Asthma
8 (154%) 1 (1.9%)
Exacerbations
Patients With Non-Severe Asthma
(28's /°)o 2 (3'8 /°)o
bations
As shown in Table 5, eight severe asthma bations were observed in the
placebo group, and only 1 severe asthma exacerbation was observed in the mAb1 treatment
group. The remaining 15 asthma exacerbations in the placebo group and 2 in the mAb1 group
met the protocol definition of exacerbation based on sed morning PEF and/or increased
albuterol/levalbuterol use. Within the active treatment group, a sustained improvement versus
baseline was observed during the course of the study for all parameters, despite steroid
withdrawal.
Table 6. bation Events
Outcome Placebo mAb1
(N : 52) ( N : 52)
2 30% reduction from baseline 10* (19.2) 1 (1.9)
in morning PEF in a 24-hr
period on 2 consecutive days
2 6 additional inhalations of 10 (19.2) 1 (1.9)
albuterol/levalbuterol in a 24-hr
period on 2 consecutive days
Systemic steroid treatment 5 (9.6) 1 (1.9)
2 4-fold increase in 108 from 3 (5.8) 0
the us dose
Hospitalization
*4 Placebo patients met both PEF and systemic steroid treatment criteria, and 1 placebo patient
met both PEF and additional albuterol/levalbuterol use.
With mAb1, the time to exacerbation was longer, and the risk of exacerbation was
reduced relative to placebo (hazard ration 0,10; 95% Cl 0.03, 0.34; P< 0.001 ). An analysis of
the time to asthma exacerbation by Kaplan-Meier Plot revealed that the effect of treatment with
mAb1 is sustained over time, including after 8 weeks when ts are at higher risk of
ping bations due to steroid withdrawal.
Only 1 patient from the placebo group had a composite asthma event. A composite
asthma event is d as a 30% or greater reduction from baseline in morning PEF on 2
utive days together with 26 additional reliever puffs of albuterol or Ievalbuterol in a 24-
hour period (compared to baseline) on 2 consecutive days.
(ii) Other Efficacy nts
Lung function parameters (FEV1, AM PEF and PM PEF), asthma symptom-based
endpoints (ACQ score, nighttime awakenings) and albuterol use were assessed for each patient
at each visit. In addition, the SNOT-22 score was assessed at baseline and at the end of
treatment. For all parameters, the baseline and Week 12 (LOCF) mean values along with the
mean difference between ent groups (ANOVA model for SNOT-22) are summarized in
Table 7. In Table 7, the column labeled rence vs. Placebo" reflects the placebo-corrected
value from baseline which takes into account changes that are observed in the value of the
parameter as compared to the changes that were observed for that parameter in the placebo-
treated group.
Table 7. Secondary Parameters of Lung Function and Symptom Scores
Least-Squared
Baseline Mean Difference vs.
(SD) MeaI:SC[h)ange Placebo p value
FEV1 (L)
Placebo 52 2.54 (0.66) -0.22 (0.06) --
mAb1 52 2.47 (0.65) 0.05 (0.06) 0.27 (0.11, 0.42) 0.0009
AM PEF (L/min)
Placebo 52 406.9 (110.7) -20.7 (9.1) --
mAb1 51 393.0 (101.1) 13.9 (8.8)f 34.6 (10.6, 58.5) 0.0051
PM PEF (L/min)
o 51 416.6 (116.8) -18.4 (8.9)1' --
mAb1 52 414.6 (102.3) 4.3 (8.5) 22.7 (-0.7, 46.0) 0.0567
rol Use (Puffs/Day)
Placebo 52 2.0 (1.8) 0 7 (0.3 --
mAb1 50 2.2 (2.4) -1 3 (0.3): -2.0 (-2.9, -1.2) <0.0001
ACQ Score
Placebo 52 2.08 (0.52) -0.27 (0.16) --
mAb1 52 2.09 (0.46) -1.00 (0.16) -0.73 , -0.30) 0.0011
Night-time Awakenings (No. of times/night)
Placebo 52 0.2 (0.5) 0.1 (0.1) --
mAb1 52 0.4 (0.8) -0.2 (0.1) -0.2 (-0.5, -0.0) 0.0518
SNOT22 Average Score
Placebo 51 26.24 (15.62) 0.23 (2.15)‘I' --
mAb1 50 30.92 (14.77) -8.26 (2.20): -8.49 (-13.96, -3.03) 0.0027
T 51 ts with at least 1 post-baseline assessment.
1; 50 patients with at least 1 post-baseline assessment.
] Treatment with mAb1 ed in a significant change from baseline in FEV1 at Week 1,
which was ined through Week 12 despite LABA and ICS withdrawal, with a small
decrease in FEV1 at Week 5 ding with LABA awal. Similar improvements were
observed in g PEF, but less so in evening PEF. The least-squared (LS) mean change
from baseline to week 12 in FEV1 was -0.22 L for placebo and 0.05 L for the mAb1 group.
(p=0.0009).
ACQ5 score improved in both treatment groups at Week 1. However, while ACQ5
improved further with mAb1 between Weeks 1 and 4, the placebo effect ized, ining
the difference through Week 12.
[00145] Morning symptom scores increased from baseline to Week 12 with placebo. With
mAb1, there was an initial decrease which remained below baseline through Week 12. A similar
pattern (with greater variability) was observed for evening asthma symptom scores.
Nocturnal awakenings were stable from the placebo group through Week 6, then
increased from Weeks 6 to 12. In contrast, nocturnal awakenings decreased in the mAb1 group
by Week 1 and remained improved versus baseline through Week 12.
Changes in albuterol/levalbuterol use were similar to other secondary endpoints: an
initial decrease ed by a return towards ne with placebo. With mAb1, the initial
decrease was maintained over time.
There was a non-significant difference at ne between the SNOT-22 values with
the mean placebo score at 26.24 and the mean mAb1 score at 39.02. At week 12, the LS mean
change was a slight increase of 0.23 points for the placebo group and a mean decrease
(improvement) of 8.26 points for the mAb1 group. This represented a magnitude of improvement
of 8.49 points for the mAb1 group (p=0.0027).
Table 8. Secondary Endpoints
Outcome Placebo mAb1 Difference vs P Value
(N = 52) ( N = 52) Placebo
(95% Cl)**
Kaplan-Meier estimate at 46.0 (31.8, 60.2) 5.8 0.10 (0.03 to 0.34) <0.001
12 weeks (0.0, 2.1)
Change in morning 0.3 i 0.1 -0.4 i 0.1 -0.7 (-0.9 to -0.4) <0.001
asthma symptom scores,
baseline to week 12
Change in evening 0.1 i 0.1 -0.6 i 0.1 -0.7 (-0.9 to -0.4) <0.001
asthma symptom ,
baseline to week 12
Table 9. Change From Baseline at Week 12 in SNOT-22 Items Relevant to Upper Airway
Disease.
SNOT-22 Subscale Least-Squares Mean Difference vs Placebo P Value
Change 1 Standard Error (95% Cl)
Placebo mAb1
(N : 52) ( N : 52)
Need to blow nose -0.70 (-1.13, -0.26) 0.002
Nasal blockage -0.20 i 0.19* -0.94 : 0.19T 0.75 (-1.22, -0.28) 0.002
Decreased sense of 0.04 i 0.18* -1.13 : 0.18T -1.16 , -0.71) < 0.001
smell/taste
*51 and f50 patients with at least 1 post-baseline assessment respectively
For all secondary endpoints, Week 12 measurements favored mAb1 treatment and
were significant except for evening PEF and nal awakenings (Table 7 and 8). icant
ements with mAb1 were also observed for the three SNOT-22 items relevant to upper
ainNay disease (Table 9)
(iii) Safety
mAb1 was generally safe and well tolerated. Treatment-emergent adverse events
(TEAEs) were reported rly by 40 (76.9%) of placebo-treated patients and by 42 (80.8%) of
mAb1-treated patients (Table 10). TEAEs were non-specific, generally mild to te in
intensity and the majority recovered by the end of the study. An increased reporting of the
following TEAEs was observed for mAb1 in comparison with placebo: ion site reactions
were reported by 15 (28.8%) mAb1 patients and by 5 (9.6%) placebo patients; aryngitis
was reported by 7 (13.5%) mAb1 patients and 2 (3.8%) placebo patients; headache was
reported by 6 (11.5%) mAb1 patients and 3 (5.85) placebo patients and nausea was reported by
4 (7.7%) mAb1 ts and 1 (1.9%) placebo patients.
Table 10. Adverse Events.
Adverse event Placebo mAb1 300 mg
(N : 52) (N : 52)
no. ofpatients (%)
Any adverse event 40 (76.9) 42 (80.8)
Any serious adverse event 3 (5.8) 1 (1.9)
Study discontinuation owing to adverse event 3 (5.8) 3 (5.8)
Death 0 0
Most common AEs*
Injection site reactionsf 5 (9.6) 15 (28.8)
Nasopharyngitis 2 (3.8) 7 (13.5)
Adverse event Placebo mAb1 300 mg
(N : 52) (N : 52)
no. ofpatients (%)
Upper respiratory tract infection 9 (17.3) 7 (13.5)
he 3 (5.8) 6 (11.5)
Nausea 1 (1.9) 4 (7.7)
Arthropod bite 0 3 (5.8)
Muscle spasms 0 3 (5.8)
Nasal congestion 1 (1.9) 3 (5.8)
Rash 1 (1.9) 3 (5.8)
Urticaria 0 3 (5.8)
Viral upper atory tract infection 0 3 (5.8)
*2 3 patients in any ent group by Preferred Term
Tlnjection site reaction includes events reported as: injection site pain, injection site reaction,
injection site erythema, injection site rash, injection site haematoma, injection site urticaria,
injection site dermatitis, injection sites inflammation, injection site nodule, injection site pruritus
and injection site ng.
There were no deaths reported during the study period. Of the 4 treatment emergent
serious adverse events (SAEs) reported: 1 mAb1 t experienced bipolar disorder and 3
placebo patients experienced SAEs of asthma with pneumonia, gunshot wound with left
pneumothorax, and right ankle fracture. None of these SAEs were ered as related to the
mAb1 and all but the recent ankle fracture were recovered by the end of the study. There were
no deaths.
A total of 6 patients discontinued the study due to a TEAE: 3 patients in the mAb1
group (bipolar disorder, asthma with wheezing, and angioedema) and 3 patients in the placebo
group (upper respiratory tract infection, psoriasis and asthma). The TEAE of angioedema
occurred in a 42-year old African-American female after the ninth study treatment dose as a
pruritic, popular rash observed at, and distant to, the ion site. It persisted for one week,
resolved after study treatment discontinuation, and prednisome and diphenhydramine
treatment. It was deemed treatment-related. This AE was subsequent to milder rashes at the
injection site after the first and sixth study treatment doses.
] Among the most common AEs occurring in 23 patients in any treatment group (Table
), ion site reactions, nasopharyngitis, nausea, and headache occurred more frequently
with mAb1 than placebo. No clinically icant changes in vital signs, physical examination,
clinical laboratory or ECG gs were reported in either group.
G. Conclusion
Significant improvements were ed for lung function and other asthma control
parameters. Efficacy was observed early and sustained despite background y
withdrawal. A relative reduction of approximately 87% (p <0.0001) in the primary endpoint of the
incidence of asthma exacerbations in persistent, moderate-to-severe asthma patients with
eosinophilia was observed after 12-week treatment with 300mg of mAb1 once weekly (5.8%)
ed with placebo (44.2%). As shown in Table 7, ally meaningful and statistically
significant ut multiplicity adjustment) improvements with treatment ed with o
were observed in lung function parameters (FEV1, PEF AM), asthma symptom scores (A00)
and albuterol use. Positive trends were obsen/ed for PEF PM 567) and nocturnal
awakenings (p=0.0518). A statistically significant (without multiplicity adjustment) improvement
was also observed for the SNOT-22 score. Within the active treatment group, a sustained
improvement versus baseline was observed during the course of study for all parameters,
despite LABA and ICS awal. mAb1 was generally safe and well tolerated.
e 2: Biomarker studies
Biomarker is was conducted on samples taken from subjects who participated in
clinical trials of mAb1 (see Example 1 above). In particular, serum/plasma biomarkers
associated with TH2 inflammation such as thymus and activation chemokine (TARC; ,
lmmunoglobulin E (lgE), n-3, periostin, carcinoembryonic antigen (CEA), YKL-40 and
blood eosinophils were measured in samples from patients at baseline and at different time
points following initiation of study treatment(s). Baseline levels of these biomarkers were
assessed for potential predictive value for treatment response. In addition, the fraction of
exhaled NO (FeNO) and induced sputum eosinophils and neutrophils were measured as
biomarkers of bronchial mation. Exhaled nitric oxide assessment was conducted prior to
spirometry and following a fast of at least 1 hour using a NIOX ment (Aerocrine AB, Solna,
Sweden). Biomarkers were analyzed using a mixed model and the least square mean d
from the model are reported below.
[00156] Asthma subjects (N=104) were administered either mAb1 (300 mg) or placebo
subcutaneously, on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71 and 78 of the study (i.e., 12
weekly doses) (see Example 1, above). Samples for biomarker analysis were collected from the
antibody- and placebo-treated subjects at week 0, 1, 4, 8 and 12. Antigen-specific lgE was
detected using the Phadiatop® test.
[00157] TARC, eotaxin-3 and lgE remained unchanged in se to placebo. In contrast, a
rapid reduction in TARC (mean % change -22.7% vs +0.3%; p: 0.0003) and eotaxin-3 (mean %
change -39.62% vs 12.69%; p<0.0001) was obsen/ed within one week in ts treated with
mAb1 and persisted until week 12: TARC: -26.0% vs +7.6% placebo (p=0.0005); Eotaxin-3: -
45.67% vs +5.13% placebo (p<0.0001).
[00158] TARC levels responded within a week following exposure to mAb1 at 300 mg
administered subcutaneously. TARC levels plateau at approximately 50% of the baseline level
in mAb1-treated subjects, regardless of ICS awal. The data suggest that TARC
expression is more directly linked to lL-4R signaling, than FEV1 changes (which drop in parallel
to ICS withdrawal [after Week 4]) and that lL-4R blockage induces a shift towards a TH1
signature, as observed with, for example, lFNgamma administration. It might be possible to
titrate the mAb1 dose using TARC (and for example CXCL10) in particular in patients requiring
long term treatment and at risk for TH1 type immune diseases.
Total serum lgE also decreased following mAb1 ent. Total serum lgE response
was more heterogeneous and delayed compared to TARC response. Mean (SD) baseline lgE
levels were 694.68 lU/L (1837.82) for the placebo group (n=52) and 657.66 (1482.25) for the
mAb1 group (n=52), whereas median was 169.95 for the placebo group and 206.15 for the
mAb1 group. Despite this heterogeneity, a trend towards lgE decrease in xposed
patients compared with placebo was obsen/ed — however, ng at week 4 only. Serum lgE
was significantly reduced in the mAb1 group compared with placebo (mean % change, -10.1%
vs +13.5%; p=0.0325) starting from week 4 and continued to decrease until week 12 (mean %
change, -36.8% for mAb1 vs -5.5% for o; p<0.0001).
Changes from baseline and placebo at Week 12 for FeNO, TARC, eotaxin-3, and lgE
all favored mAb1 (all P< 0.001) (Table 11). No differences from ne or n treatments
were observed in YKL-40 or CEA.
Table 11. Percent Change From Baseline at Week 12 in Pharmacodynamic Endpoints.
Least-Squares Mean Percent
Change 1 Standard Error
e P Value
Placebo mAb1
(N : 52) (N : 52)
FeNO 35.0 i 10.8 28.7 i 11.2 < 0.001
TARC 7.6 i 6.9 -26.0 i 6.9 < 0.001
Eotaxin-3 5.1 i 4.7 -45.7 i 4.7 < 0.001
lgE 5.5 i 3.6 -36.8 i 3.6 < 0.001
Blood phils 2.7 i 15.8 41.6 i 15.7 0.078
There was a transient decrease in tin levels, followed by an increase with
LABA/ICS withdrawal. Administration of mAb1 delayed the increase, but did not prevent the
increase above baseline. No consistent treatment effect was observed with CEA and YKL-40.
The number of blood eosinophils remained unchanged through Week 6, but then increased at
Weeks 8 and 12. Peripheral blood eosinophil numbers were ged on placebo throughout
treatment. The difference between the treatments was not significant, with the borderline
increase driven by larger blood phil elevations in only a few ts treated with mAb1.
Little or no increases were obsen/ed in the majority of patients.
Table 12. Proportions of Patients Achieving Thresholds of Change in Blood Eosinophil
Levels.
Change in phils Number (%) of patients
Placebo (n = 52) mAb1 (n = 52)
> 15% Decrease 13 (30.2) 21 (47.7)
% Decrease — 0% change 7 (16.3) 6 (13.6)
0%-15% Increase 8 (18.6) 4 (9.1)
% - 100% Increase 13 (30.2) 6 (13.6)
100% - 200% increase 2 (4.7) 3 (6.8)
> 200% increase 0 4 (9.1)
Since only 3 mAb1 patients experienced asthma exacerbation during the study, no
conclusion could be drawn regarding the association n baseline biomarker levels and
asthma exacerbations.
mAb1 treatment was also associated with a significant decrease from baseline in FeNO
at Week 4, and FeNo remained below baseline through Week 12, regardless of lCS withdrawal
(mean % change at week 12: -28.7 for mAb1 vs 35.0 for placebo; p<0.0001). In contrast,
placebo FeNo values remained stable through Week 8, followed by an increase at Week 12
coincident with lCS withdrawal.
Forced expiratory volume in 1 second (FEV1) ement significantly correlated with
FeNO reduction ( =-0.408, 9) at week 12. Similarly, improvements in AM-PEF and PM-
PEF correlated with FeNO reduction. Other correlations with FeNO were not significant. See
Table 13.
Table 13. Correlation between FEV1 and PD Endpoints.
Outcome Correlation P Value
FeNO -0.408 <0.009
TARC -0.248 0.10
Eotaxin-3 -0.146 0.34
lgE -0.279 0.06
Blood eosinophils 0.165 0.28
] Scatter plot analysis of baseline phils versus change from baseline in FEV1 at
week 12 did not seem to suggest association of baseline eosinophils and ent effect, as
measured by change from baseline in FEV1 at week 12 in the study tion (baseline
eosinophils 2 0.3 Giga/L). Baseline eosinophils correlated with decreased ACQ and sed
albuterol/levalbuterol use. Periostin and YKL-40 at baseline correlated with decreased ACQ.
The FEV1 change from baseline at week 12 was compounded by the withdrawal of lCS
(starting at week 4). Similar analyses did not suggest ation between baseline TARC or
lgE and change from baseline in FEV1 at week 12 in the study population (baseline eosinophils
2 0.3 Giga/L).
H. Summary
] These results show that mAb1 significantly reduced serum biomarkers associated with
Th2 inflammation (TARC, eotaxin-3 and lgE) and bronchial mation (FeNO) in adult asthma
ts. The correlation between FeNO reduction and FEV1 improvement suggests a
onship between lL-4/lL-13 mediated anti-inflammatory activity and ement in
pulmonary function in moderate-to-severe, uncontrolled asthma.
Example 3. Clinical Trial of Subcutaneously Administered Anti-lL-4R Antibody (mAb1) In
Patients with Bilateral Nasal Polyposis and Chronic Symptoms of Sinusitis
A. Study Objectives and Overview
] The positive effect of mAb1 on the SNOT-22 test described in e 1 suggested
that the anti-lL-4R antibody might also be effective for treating nasal polyposis. Further, nasal
polyps are most commonly philic/TH2 driven, and mAb1 significantly reduced biomarkers
associated with Th2 inflammation (see Example 2). A clinical trial was therefore designed to
test the therapeutic effect of mAb1 on nasal polyposis.
[00169] A randomized, double-blind, phase 2, placebo controlled, 2 arm study will be performed
to evaluate mAb1 administered once a week (QW) subcutaneously (SC) for 16 weeks in
patients with bilateral nasal polyposis and c symptoms of tis. The primary objective
of the study will be to evaluate the efficacy of mAb1 in the treatment of bilateral nasal polyposis
(NP) by assessment of the endoscopic nasal polyp score in ison to placebo. Secondary
objectives of the study include evaluation of mAb1 in patients with bilateral nasal polyps with
regards to symptoms of sinusitis, Computed Tomography (CT) scan changes, Nasal polyp score
in the sub-group of patients with co-morbid asthma, safety and bility, pharmacodynamic
responses based on suppression of TH2 biomarkers, concentrations of mAb1 in serum, immune
response to mAb1 (Anti-drug antibodies (ADA)), and effect of mAb1 in patient reported
outcomes and Quality of Life (QoL) scales.
mAb1 will be administered concomitantly with Mometasone furoate nasal spray
(MFNS). Also, there is high co-morbidity of NP with asthma, aspirin/ roidal anti-
matory drug (NSAID) hypersensitivity and previous surgeries, and therefore ts will
be allowed to enter the study unless they present any of the exclusion criteria described below.
Approximately 56 patients will be ized into 2 treatment groups of 28 patients per group.
To ensure at least 28 patients with co-morbid asthma are included in the study, recruitment of
NP patients without co-morbid asthma will stop when approximately 28 patients without asthma
are randomized. Both the patient and the investigator will be blinded to the assigned treatment
group.
[00171] The study will consist of three periods: 1) a four week screening run in period on
MFNS (Visit 1); (2) a 16 week randomized mAb1 or placebo treatment period (Visits 2-18); and
(3) a 16 week reatment period to assay cokinetics, immunogenicity, safety and
efficacy (Visits 19-22). The total duration of the study is up to 36 weeks.
The primary endpoint will be the change from baseline at Week 16 in bilateral nasal
polyp score (NPS).
Numerous secondary efficacy endpoints will be measured to more comprehensively
evaluate the efficacy of mAb1. The study will e improvement of nasal polyposis and
associated sinus mation in CT scan, improvement in condition specific and general
medical questionnaires in order to obtain a better understanding of the impact of severe nasal
polyposis on the t's quality of life (QOL).
These endpoints, together with exploratory sub-group analysis and biomarkers will
provide the information on the therapeutic value of mAb1 to reduce nasal polyp score and to
improve ms in NP and its subsets. The sustainability of the effect will be also explored
through the 4-month post-treatment evaluation period.
The 300 mg QW dose n is anticipated to saturate apparent target mediated
clearance level (10-15 mg/L). This regimen has been tested and ed statistically significant
and clinically relevant response in two previous proof of concept studies med with mAb1
in asthma and atopic dermatitis (see, e.g., Example 1 above, USSN 61/805797 and
USSN 61/816191). The first dose will employ a loading dose of 600 mg in order to achieve
faster steady-state concentration. This loading dose range is supported by the acceptable safety
profile of the highest loading dose (600 mg) trated in a prior study conducted in
Japanese healthy subjects.
[00176] In addition, given that the Cmax after 600 mg loading dose is around 70 mg/L and that
the steady state h of 300 mg QW is around 150 mg/L, the Cmax after the proposed
dosing regimen (ie, 600 mg loading dose followed by 300 mg QW) will be below the mean Cmax
of 12 mg/kg lV dose (421 mg/L), the highest single dose tested in healthy ts that was well
ted, providing additional confidence that this dose regimen should have an able
safety profile.
Patient inclusion criteria include (i) a physician endoscopic diagnosis of bilateral nasal
polyposis (ie, a minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both
nostrils, with at least a score of 2 for each nostril, despite completion of a prior INCS (intranasal
corticosteroid) treatment) for at least 8 weeks before ing, and (ii) chronic symptoms of
sinusitis, which are the presence of at least two of the following ms prior to screening:
nasal blockade/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); facial
ressure; and reduction or loss of smell.
Patients who have met these criteria will be screened for the following exclusion
criteria: age <18 or >65 years; any technical/administrative reason that makes it impossible to
randomize the patient in the study; previous participation in any clinical trial of mAb1 ; a SNOT22
score <7; receipt of any other investigational drug or prohibited therapy for this study within 2
months before screening or 5 half-lives, whichever is longer; receipt of oral corticosteroids
(008) or intranasal corticosteroid drops within 2 months or 1 month before screening or
scheduled to receive OCS during the study period for another condition; treatment with mAB or
immunosuppressive therapy; treatment with an anti-immunoglobulin E (IgE) therapy (e.g.,
omalizumab) within 130 days of Visit 1; treatment with a leukotriene antagonist / modifier for
patients who were not on a continuous treatment for 230 days prior to Visit 1; initiation of
en immunotherapy within 3 months prior to Visit 1 or a plan to begin y during the
Screening Period or the Randomized ent Period; any nasal surgery within six months
before screening or have had more than five sal surgeries in the past of which maximal
two were surgeries changing the lateral wall structure of the nose; or a condition/concomitant
e that makes a patient non-evaluable for the primary efficacy endpoint (e.g., antrochoanal
polyps; nasal septal deviation that would occlude at least one nostril; acute sinusitis, nasal
infection or upper respiratory infection at screening or in the 2 weeks before screening; ongoing
rhinitis medicamentosa; Churg-Strauss syndrome, Young’s syndrome, Kartagener’s syndrome
or dyskinetic ciliary syndromes, Cystic fibrosis; signs or a CT scan suggestive of Allergic fungal
rhinosinusitis). Patients with co-morbid asthma are excluded if: the patient has a forced
expiratory volume (FEV1) of 60% or less; an exacerbation requiring systemic (oral and/or
parenteral) steroid treatment or Hospitalization (>24h) for treatment of , has occurred
within 3 months prior screening; or the patient is receiving a dose higher than 1000 pg
fluticasone or the equivalent of d osteroids. Other exclusion criteria include patients
with short life expectancy (less than 6 ); patients receiving concomitant treatment
prohibited in the study; women who are pregnant or intend to become pregnant during the study,
or breast-feeding women. Other exclusion criteria include concomitant severe diseases (e.g.,
active and inactive pulmonary tuberculosis, es mellitus etc.); diagnosed active parasitic
infection; suspected or high risk of parasitic infection; history of human immunodeficiency virus
(HIV) ion or positive HlV screen at Visit 1 ; evidence of acute or chronic infection; known or
suspected immunosuppression, including history of invasive opportunistic infections (eg,
tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis),
despite ion resolution; live vaccinations within 12 weeks prior to Visit 1 or planned
vaccinations during the study; patients with active autoimmune disease or patients using
immunosuppressive therapy for autoimmune disease (eg, Hashimoto’s thyroiditis, Graves’
disease, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematous,
le sclerosis, psoriasis vulgaris, toid arthritis); patients with positive or indeterminate
hepatitis B e n (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody
at Visit 1; patients with liver injury related criteria ( e.g., underlying hepatobiliary disease, or
ALT>3 ULN).
B. Study ents
lnvestigational Product: Sterile mAb1 of various trations will be provided in 5 mL
glass vials. Each vial will n a withdrawable volume of 2 mL: 150 mg/mL solution (300 mg
dose/ 2 mL). Sterile placebo will be provided in cally matched glass 5 mL vials, where
each vial contains a deliverable volume of 2 mL.
mAb1 will be administered every 7 :r 2 days (QW). The doses of mAb1 will be
separated by 25 days to avoid an overdose. At Visit 2 (V2), 2 injections will be performed. After
V2 one ion of mAb1 will be performed weekly at the investigational site throughout the
randomized treatment period. The mAb1 will be administered following clinic procedures and
blood collection. ts will be monitored for at least 1 hour after each administration for any
signs or symptoms of a local site injection or hypersensitivity reaction. Subcutaneous injection
sites will be alternated between the 4 quadrants of the abdomen (avoiding navel and waist
areas) or upper thighs so that the same site is not injected for two consecutive times/weeks.
On a daily basis throughout the study, the subject will use an onic diary to record
daily use of MFNS. Mometasone furoate (NASONEX ®) 50 rams/actuation Nasal Spray,
is contained in a bottle, that contains 18 g (140 actuations) of product formulation.
[00182] Screening Period: Prior to ing, subjects must be on a stable dose of intranasal
osteroids (INCS) for 22 month prior to Visit 1. If the patient is using an alternative INCS
product other than MFNS prior to the screening visit, at V1, the patient will be switched to
MFNS. After V1 all ts will enter a run-in period of 4 weeks where they will receive MFNS:
2 actuations (50 ug/actuation) in each l twice daily (BID) (total daily dose of 400 pg),
unless they are intolerant to BID INCS in which case, they can stay on the lower dose (QD)
regimen. To be accepted for the study, patients must also have presence of at least two of the
following symptoms prior to screening: Nasal blockade/obstruction/congestion or nasal
discharge (anterior/posterior nasal drip); +/- facial pain/pressure or +/- reduction or loss of smell
[00183] Treatment Period: The treatment period will proceed as indicated in the Study Flow-
chart at Table 14.
Table 14.
Screenin Randomized ent period Post-treatment
9 period period
Inclusion Criteria X X
including Informed
Consent s
Exclusion Criteria
Screenin ized treatment period Post-treatment
g period penod
RDN E
VISIT 1 2 15 16 17 18 19 20 21
Week (DAY) W-4(D- W0 14 4
28) (D1)
Medical/Surgical X
History
Prior Medication X
Historyb
Physical X X
Examination
Spirometryc X X
Treatment:
mAb1 weekly SC
administrationd
Call IVRS
Dispense or x x
download
onic
diary/NPIFe
NIMP (MFNS)
Record
concomitant
medication
Efficacy
CT scan9
Smell test (UPSIT)
SNOT- 22
Visual analogue
scale (VAS)
QoL (SF-36, EQ-
Nasal polyp related
resource use
questionnaire
ACQ-5h
Safet
AE /SAE
recording (if any)
Vital Si 0 ns
Laboratory
Testing
Screenin Randomized treatment period Post-treatment
g period period
VISIT 1 l\) oo 4> \l 15 16 17 18 19 20 l\) _\
Week (DAY) w-4( UI Eo l\) coo-I 4; O) 13-1614 20 l\)4; l\) 00
28) (D1)
Clinical laboratory x >< ><
testingi
ysis X
diostick
Pregnancy test (for X x ><
WOCBPJ'
PK/Anti-drug >< >< ><
antibody sampling
PKk .-><
Serum Biomarker >< >< ><
sampling
Archival nasal X ><
secretion
samplingm -I---E— -uuuuumm
Polyp biopsyn -
Stored DNA
sampling I-
Stored whole blood X >< X
RNA ng0 E
The Screening Period is 28 days in duration to run in any patient on MFNS, and to collect baseline data. V2
will take place 28days+/-2 day window after V1
3 No mAb1 administration during this visit. ts who discontinue treatment early will be assessed as
soon as possible using the procedures normally planned for the -treatment Visit and the 4 Post-
treatment Period Visits.
b Prior to screening, patients must be on a stable dose of INCS for more than 8 weeks
0 Spirometry: all patients should have FEV1 anytime during Screening Period (before V2) and at the other
scheduled visits during the Randomized treatment period
d Weekly mAb1 administrations ng from V2 at the site investigational site must be separated by at
least 5 days.
9 Electronic diary/NPIF meter is used for daily recording of MFNS use, nocturnal awakenings, morning
and evening NPIF and rhinosinusitis m scores 1) nasal congestion/obstruction 2) anterior
rhinorrhea (runny nose), 3) posterior rhinorrhea (post nasal drip), and 4) loss of sense of smell, scored
using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and
3 = severe symptoms); This device is sed at Visit 1 and information is downloaded from this
device on the other indicated days. The e of the last 7 days before V2 is needed to ine the
baseline value
f Nasal endoscopy: endoscopy (including use of decongestants before the procedure) will be performed
after all other efficacy assessments have been completed for each visit; Standard video sequences will
be downloaded by the investigator to the central reader’s secured Internet site. For eligibility central
reading of V1 will be used. At V2 investigator review V1 results from central reader to confirm entry
criteria and reconfirm eligibility based on review of Inclusion/Exclusion Criteria and the V2 opy
local reading
g CT scan should be performed e during Screening Period before a first administration of mAb1 and
at EOT. Central reading will be used for comparison baseline (BL) to EOT
h Only for patients with co-morbid asthma, ACQ-5 is completed in the patient’s electronic diary during clinic
visits.
i Hematology: hemoglobin, hematocrit, et count, total white blood cell count with five-part differential
count, differential count, and total red blood cell count. Serum chemistry (Obtain fasting at planned visits
but V2): creatinine, blood urea nitrogen, e, uric acid, total cholesterol, total protein, albumin, total
bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, electrolytes
m, potassium, chloride), bicarbonate, and creatine phosphokinase. Clinical laboratory testing at
Visit 1 includes hepatitis screen (hepatitis B surface antigen (HBsAg), Hepatitis B lgM core antibody
(HBcAb-lgM), hepatitis C antibodies (HC Ab), HIV screen (Anti-HlV-1 and HIV-2 antibodies), anti-nuclear
antibody (ANA). al laboratory testing at Visit 2 is limited to hematology and a separate hematology
sample obtained for local analysis. Note: Anti-ds DNA antibody will be tested if ANA is ve (21:160
titer). Clinical lab testing at Visit 2 consists of hematology only
j Serum pregnancy test at Visit 1 and urine pregnancy tests at other . A negative result must be
obtained at Visits 1 and 2 prior to randomization visits
k Serum pharmacokinetic samples, immune response assessment (ADA) samples and optional whole
blood RNA samples will be ted prior to administration of investigational product during the
Randomized Treatment . During the post-treatment period PK samples will be collected at all visits
and ADA s only at EOS visit. Patients with titers >1000 of the ADA at last visit may be followed
after the study. Blood samples for PK and ADA ment will be collected at any time iln case an
SAE occurs.
m Nasal secretion samples will be collected and stored for potential future discovery efforts to identify
tors of treatment response
n Optional polyp biopsies will be collected in selected clinical s
0 Samples will be collected prior to administration of investigational product during the Randomized
ent Period
[00184] During the Treatment , patients will ue the stable dose of mometasone
furoate: two actuations of MFNS in each nostril BID or QD (in case patient cannot tolerate the
high dose). At Visit 2, patients will be administered the SNOT-22 test, VAS and QoL
questionnaires , EQ-5D, Nasal polyp related resource use questionnaire), the smell test,
and the ACQ-5 in patients with asthma.
[00185] al laboratory testing at Visit 2 is limited to hematology, pharmacokinetics, anti-
drug antibodies, biomarkers in serum and plasma, allergen-specific lgE panel sampling. Blood
samples are taken prior to administration of mAb1. Nasal secretion sampling for biomarkers.
For those ts who have signed a specific informed consent form, collect blood sample for
DNA and RNA sampling (prior to administration of investigational product during the
40 Randomized ent Period).
Temporary treatment discontinuation may be considered by the Investigator because of
suspected AEs. Reinitiation of treatment with mAb1 will be done under close and appropriate
clinical/and or laboratory monitoring once the igator will have considered according to
his/her best medical judgment that the responsibility of mAb1 in the occurrence of the concerned
45 event was unlikely and if the selection criteria for the study are still met.
An adverse event (AE) is any rd medical occurrence in a patient or clinical
investigation patient administered a pharmaceutical product and which does not necessarily
have to have a causal relationship with this treatment.
A serious e event (SAE) is any untoward medical occurrence that at any dose:
results in death, or is life-threatening, (the term threatening” in the definition of “serious”
refers to an event in which the patient was at risk of death at the time of the event; it does not
refer to an event which hypothetically might have caused death if it were more severe); requires
inpatient hospitalization or prolongation of existing hospitalization, or results in persistent or
significant disability/incapacity, or is a congenital anomaly/birth defect; is a medically important
event Medical and scientific judgment should be exercised in deciding whether expedited
reporting is riate in other situations, such as important medical events that may not be
immediately life-threatening or result in death or alization but may jeopardize the patient or
may require ention (ie, specific measures or corrective treatment) to prevent one of the
other outcomes listed in the definition above (he following list of medically important events is
intended to sen/e as a guideline for determining which condition has to be considered as a
medically important event. The list is not ed to be exhaustive: intensive treatment in an
emergency room or at home for: Allergic bronchospasm, anaphylaxis, blood dyscrasias (ie,
agranulocytosis, aplastic anemia, bone marrow aplasia, myelodysplasia, pancytopenia, etc),
convulsions (seizures, epilepsy, epileptic fit, absence, etc), pment of drug dependency or
drug abuse); ALT >3 x ULN + total bilirubin >2 x ULN or asymptomatic ALT se >10 x ULN;
Suicide attempt or any event suggestive of suicidality; syncope, loss of ousness (except if
documented as a consequence of blood sampling); bullous cutaneous eruptions; Cancers
diagnosed during the study or aggravated during the study; c neurodegenerative diseases
(newly diagnosed) or aggravated during the study (only if judged unusual/significant by the
Investigators in s assessing specifically the effect of a study drug on these diseases).
Post-treatment Period: Upon completing the Randomized ent Period (or
following early discontinuation of mAb1), ts will continue treatment with the stable dose of
MFNS maintained over the randomized treatment period, or modify ent based on medical
judgment.
The following concomitant treatments are not permitted during the Screening Period
and the Randomized treatment period: use of intranasal medication that would interfere with the
symptoms of diseases (antihistamines, nasal ne, ipratropium bromide, nasal cromolyn),
except nasal saline; INCS drops; systemic corticosteroid; decongestion (topical or ic),
except before endoscopy; long term use of systemic antibiotics (for 2 weeks or more);
lipoxygenase tors; any immunosupressive treatment including but not limited to
rexate, cyclosporine, mycophenolate, tacrilomus, gold, llamine, sulfasalazine,
hydroxychloroquine, oprine, cyclophosphamide; anti-immunoglobulin E (lg E) therapy
(omalizumab); and aspirin or NSAID in patients with hypersensitivity to aspirin.
] The following concomitant treatments are allowed: MFNS during the screening and
throughout the whole study; Nasal normal saline; Topical decongestants (e.g., Oxymetazoline
hydrochloride to reduce the swelling and widen the path for the endoscope), as well as a topical
anesthetic e.g. Lidocaine are allowed before endoscopy; short term use of Antibiotics
ks); and for patients with asthma, SABA, LABA, and Methylxanthines (e.g., theophylline,
aminophyllines). The following inhaled corticosteroids are allowed for patients on a stable dose
$1000 pg Fluticasone (or the equivalent dose of another inhaled CS; see Table 16) and only for
ts that were on a stable dose 230 days prior to Visit 1 : Leukotriene antagonists / ers
are permitted during the study, only for patients that were on a continuous treatment for 230
days prior to Visit 1; Systemic antihistamines; and Initiation of allergen immunotherapy (allergen
immunotherapy in place for 23 months prior to Visit 1 is permitted).
C. Efficacy of treatment
The primary endpoint of this study is the change from baseline at week 16 in bilateral
endoscopic Nasal Polyp Score.
Table 15.
Pol score Polyp size
0 No polyps
1 Small polyps in the middle meatus not reaching below the inferior
border of the middle ate
2 Polyps ng below the lower border of the middle turbinate
3 Large polyps reaching the lower border of the inferior turbinate or
polyps medial to the middle turbinate
4 Large polyps causing complete obstruction of the inferior nasal cavity
Nasal endoscopy will be performed at the end of the scheduled visits and preceded by
local administration of anaesthetic drugs in combination with a decongestant. rd video
sequences will be downloaded or sent to a centralized reader. Centralized imaging data
assessments and scoring by an independent physician reviewer for the imaging data will be
performed for all endoscopies. To confirm eligibility at V2, only the V1 central reading will be
made ble to the site. The final results of central reading will be made available after the
study.
For the analysis of the primary nt, central reading of V2 will be used for
comparison with EOT reading. The sites will remove subject-identifying information from the
imaging data header prior to sending the imaging data to the l reader.
Secondary nts of the study will include change from baseline at Week 16 in:
patient reported symptoms (including 22-item Sinonasal Outcome Test (SNOT-22)); t-
assessed nasal congestion/obstruction, anterior rhinorrhea (runny nose), posterior rhinorrhea
(post nasal drip), and loss of sense of smell, (daily AM and PM e-diary) month average; number
of nocturnal awakenings; patient-rated rhinosinusitis ms severity using a visual analog
scale (VAS); 5-item Asthma control questionnaire ) in asthma sub-group); nasal peak
atory flow (NPIF); smell test (UPSIT); NPS in patients with co-morbid asthma; CT scan
assessments; Spirometry (overall and in sub-group with ); time to first response (21 point
improvement) in NPS; time to study treatment discontinuation; and incidence of treatment
discontinuation due to need for OCS or nasal y.
Quality of life (QoL) end points will include change from baseline at Week 16 in: 36-
item short form health sun/ey (SF36); European y of life scale (EQ-5D); and Nasal polyp
d resource use questionnaire.
Disease-specific efficacy es include: Computed tomography (CT). CT of the
sinuses should be performed before V2 and at EOT. For both Lund-Mackay scores and 3D
volumetric measurement of the maxillary sinus, the same acquisitions nces) will be used
for centralized imaging data assessments and scoring by an independent physician reviewer for
the imaging data. Central reading of V2 will be used for comparison with EDT. The final results
of l reading will be made available after the study.
[00220] For Three-Dimensional volumetric measurement of the maxillary sinus, central reading
before V2 will be used for ison with EOT reading. The sites will remove subject-
identifying information from the imaging data header prior to sending the imaging data to the
central reader. The % change in opacification from BL to EOT will be calculated.
At screening (Visit 1), patients will be issued an NPIF meter for recording morning (AM)
and evening (PM) NPIF. The patients will be instructed to record the following variables in the
e-diary on a daily basis: AM NPIF performed within 15 minutes after arising (between 6 am and
am) prior to taking MFNS; and PM NPIF performed in the evening (between 6 pm and 10
pm) prior to taking MFNS.
Three NPIF efforts will be med by the patient; all 3 values will be recorded by the
patient in the e-diary, and the highest value will be used for evaluation. The baseline AM NPIF
will be the mean AM measurement recorded for the 28 days prior to the first dose of
investigational product, and baseline PM NPIF will be the mean PM measurement recorded for
the 28 days prior to the first dose of investigational product.
To assess disease-specific, daily symptoms, the patient will use an electronic diary to:
respond to the morning and evening individual rhinosinusitis symptom questions using a 0-3
categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 =
severe ms), and including the ms of tion and/or obstruction, anterior
rhinorrhea (runny nose), posterior rhinorrhea (post-nasal drip), and loss of sense of smell. The
number of nal awakenings will also be recorded.
The same safety ments will be d across all arms. e events,
including serious adverse events (SAEs) and adverse events of special interest (AESI), will be
collected at every visit.
[00225] e blood samples will be collected for determination of serum functional mAb1
and anti-mAb1 antibodies as designated in Table 14.
Optional ng for exploratory analysis of DNA and RNA, requiring separate
pharmacogenetics informed consent.
[00227] cokinetics. Functional mAb1 and anti-mAb1 antibodies in serum will be
assayed by ELISA. Predose functional mAb1 concentrations in serum at Visit 2 (Day 1), mAb1
trough concentrations at Week 2, Week 4, Week 8, Week 12, Week 16, and follow-up serum
mAb1 at Week 20, Week 24, Week 28 and Week 32 will be ed. Anti-mAb1 antibody
status (negative or titer value) at Visit 2 (Day 1), Week 2, Week 4, Week 8, Week 12, Week 16,
and Week 32 will also be provided. Patients with ADA titers 21000 at the end of study visit will
be scheduled to return approximately 6 months later for an additional assessment of ADA titer.
Further follow-up will be considered based on the overall assessment of antibody titers and
clinical presentation.
[00228] Pharmacodynamics. Since the secretion of certain proteins is dependent, at least in
part, on Th2 cytokines and is associated with chronic mation of the ainNay mucosa,
including sinus tissue, expression of certain biomarkers will be assayed to monitor a therapeutic
effect of mAb1. These biomarkers also will be assessed for their value in predicting toxicity
and/or in documenting the time course of drug se. The values to be used as baselines
will be those collected on Day 1 (predose assessments).
Nasal secretions will be obtained by inserting nasal swabs bilaterally into the nasal
cavity for five minutes. The nasal secretions will be presen/ed for possible analysis of additional
biomarkers related to nasal polyposis and responses to mAb1 treatment.
At selected clinical site (s) and with ic informed t, nasal polyp tissue will be
optionally obtained by biopsy. A baseline biopsy will be obtained at V2 of the study. After
randomization, another biopsy of nasal polyp tissue will be obtained at the end of treatment visit
(Week 16).
The biopsied nasal polyp tissue will be assessed for various biomarkers of inflammation
and disease process or se. For example, RNA will be extracted and used for expression
profiling (e.g., microarray, transcriptome sequencing or quantitative ).
DNA and RNA samples may be used to determine a possible relationship between
genes and response to treatment with mAb1 and possible side s to mAb1.
[00236] Analysis of proportion of patients with binary events. Proportion of patients with binary
events will be assessed for : 21 point improvement (reduction) in NPS at week 16 (as read
lly); 10% or more improvement in CT opacification from baseline at week 16; drop-out
due to oral CS or surgery; or INCS increase after 8 weeks will be analyzed using a logistic
model with the above responses, respectively, as the response variable, and treatment group,
pooled countries /regions and the stratification factor(s) prior to the study as ates.
Analysis of time to event variables. Time to event (e.g., the first se with 21 point
improvement (reduction) in NPS, study treatment discontinuation, etc) will be analyzed suing a
Cox regression model with time to event as the dependent variable, and ent, pooled
countries/regions, asthma comorbidity prior to the study as covariates. The Kaplan-Meier
method will be used to derive the proportion of patients with an event at Week 4, 8, 12 and 16
specific to each treatment group. For is during the treatment period, if a patient has no
event before treatment discontinuation/completion, then the patient will be considered as free of
event till the end of treatment period (last dose date + 7 days).
Analysis of change from baseline for continuous variables. The change from baseline
at week 16 in: NPS for patients with co-morbid asthma; Lund Mackay score; 22-item Sinonasal
Outcome Test (SNOT-22); Subject-assessed congestion and/or ction score; nasal peak
inspiratory flow (NPIF); ACQ-5 in patients with co-morbid asthma; QoL measures (SF36, EQ-
5D), and VAS will be analyzed using MMRM same as the primary endpoints. Descriptive
statistics including number of patients, mean, standard error and LS means will be provided. In
addition, differences in LS means, the corresponding 95% Cl and the p-value will be provided
for comparisons of each dose against o.
is of cy in baseline biomarker of characteristics defined subsets. To
e baseline biomarkers for their potential value to predict ent response, es of
change in NPS will also be performed for the following subsets and the entire lTT population by
each dose group and selected pooled dose group.
Subgroup analysis. To assess the consistency treatment effects across the subgroup
levels and to examine baseline biomarkers for their potential value to predict treatment
response, exploratory subgroup analyses will be conducted for the change from baseline in NPS
with respect to age group, gender, region, race, INCS dose level, baseline NPS, baseline CT
scan score, asthma comorbidity, and selected biomarkers prior to the study.
Listings of anti-mAb1 antibody results (Negative or titer value) will be presented by
patient, time point and treatment groups. ADA titer levels will be classified into categories: Low,
moderate and high. Low levels of ADA titers are defined as titers below 1000; moderate levels of
ADA titers are d as titers n 1000 and 10,000; high levels of ADA titers are defined
as titers >10,000.
Anti-mAb1 antibody assay s will be described categorically. The following
y will be provided for: Patients with any positive ADA assay response during the TEAE
period; Patients with treatment induced positive ADA assay response during the TEAE period;
Patients with treatment induced ve ADA assay se during the TEAE period will be
further described as patients with transient positive se and patients with persistent
positive response. Patients with any positive ADA assay se during the TEAE period is
defined as those having at least one sample positive in the ADA assay.
[00243] The treatment induced positive ADA assay response is defined as: ts with no
ve assay response at baseline but with a positive assay response during the TEAE period
or ts with a positive ADA assay response at baseline and also have at least a 4-fold
increase in titer during the TEAE period.
A persistent positive response is a treatment induced positive ADA assay response in
which at least 2 consecutive post-baseline samples from a patient are positive in the ADA assay
or the last post-baseline sample collected is positive in the ADA assay. A transient positive
response is defined as any treatment induced positive ADA assay response that is not
considered persistent.
Table 16. Allowable lnhaled Glucocorticosteroid / Long-Acting Beta2 Agonist Combination
Products and Acceptable Dosage Form, Strength and Dosage Schedule
Generic Name Brand Name Acceptable Acceptable Dosage Form, Strength
Product and Dosage le
Fluticasone propionate and Advair®/ DPI (250/50 or DPI: 1 puff twice daily (500/50)
salmeterol de® 500/50) DPI: 1 puffs twice daily (250/50)
115/210r MDI: 2 puffs twice daily (115/21)
230/21) MDI: 2 puffs twice daily (230/21)
Budesonide and formoterol Symbicort® DPI (200/6 or DPI: 1 puff twice daily (400/12)
400/12 DPI: 2 puffs twice daily (200/6)
MDI (160/4-5) MDI: 2 puffs twice daily 5)
Mometasone furoate and Dulera® MDI ( 100/5 or MDI: 2 puffs twice daily (200/5)
formoterol 200/5) MDI: 2 puffs twice daily (100/5)
The present invention is not to be limited in scope by the specific embodiments
described herein. Indeed, various cations in addition to those described herein will
become apparent to those skilled in the art from the foregoing description and the
anying figure. Such modifications are intended to fall within the scope of the appended
claims.
Claims (30)
1. Use of an antibody, or antigen binding fragment thereof, that specifically binds an interleukin-4 receptor (IL-4R) for the preparation of a pharmaceutical composition for treating chronic rhinosinusitis with nasal polyposis (CRSwNP) in a subject, and wherein the antibody, or antigen-binding fragment thereof, comprises: three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 ses the amino acid sequence of SEQ ID NO:3, the HCDR2 ses the amino acid ce of SEQ ID NO:4, the HCDR3 comprises the amino acid sequence of SEQ ID NO:5, the LCDR1 ses the amino acid sequence of SEQ ID NO:6, the LCDR2 comprises the amino acid sequence of SEQ ID NO:7, and the LCDR3 comprises the amino acid ce of SEQ ID NO:8.
2. The use of claim 1, wherein the subject has chronic rhinosinusitis with bilateral nasal polyposis.
3. The use of claims 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises: a heavy chain variable region (HCVR) having the amino acid ce of SEQ ID NO: 1; and a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 2.
4. The use of any one of claims 1-3, wherein the t has one or more of asthma, aspirin hypersensitivity, or hypersensitivity to a non-steroidal anti-inflammatory drug (NSAID).
5. The use of any one of claims 1-4, wherein the subject has severe nasal polyposis.
6. The use of any one of claims 1-5, wherein the composition is formulated for administration as a single initial dose and one or more secondary doses.
7. The use of claim 6, wherein the initial dose and one or more secondary doses are each about 300 mg. 06_1 (GHMatters) P39476NZ01
8. The use of claim 6 or78, wherein the ceutical composition is formulated for administration every two weeks.
9. The use of any one of claims 1-8, wherein the pharmaceutical ition is ated for subcutaneous, intravenous or intranasal administration to the t.
10. The use of any one of claims 1-9, wherein the subject has nasal polyposis which persists after a treatment regimen with inhaled corticosteroids (INCS) or after the subject stops receiving INCS.
11. The use of any one of claims 1-10, wherein the subject is selected based on one or more of the following criteria: i) a m bilateral nasal polyp score of 5; ii) an elevated level of one or more genes selected from the group consisting of thymus and activation-regulated chemokine (TARC), eotaxin-3, periostin, carcinoembryonic antigen (CEA), and YKL-40; and iii) an elevated level of blood eosinophils or sputum eosinophils.
12. The use of any one of claims 1-11, for improving one or more of: a) 22-item sinonasal outcome test (SNOT-22) score; b) nasal symptom score; c) number of nocturnal awakenings; d) visual analog score (VAS); e) five-item asthma l questionnaire (ACQ5) score; f) nasal peak inspiratory flow (NPIF); g) University of Pennsylvania Smell identification test (UPSIT); h) Lund-McKay Score; and 17032506_1 (GHMatters) P39476NZ01 i) three-dimensional tric measurement of the maxillary sinus, in particular an increase in one or both of NPIF and UPSIT and/or a decrease in in one or more of SNOT-22 score, nasal symptom score, VAS, Lund-McKay Score and 3DVolumetric Score.
13. The use of any one of claims 1-12, for decreasing a nasal polyp score.
14. The use of any one of claims 1-13, for increasing one or both of NPIF and UPSIT.
15. The use of any one of claims 9-14, wherein the pharmaceutical composition is formulated for aneous administration to the subject with a pen delivery device or an autoinjector, or formulated for subcutaneous or intravenous administration with a standard e and needle.
16. The use of any one of claims 1-15, wherein the dy is mab.
17. The use of any one of claims 1-16, wherein the ceutical composition is formulated for administration with a second therapeutic agent before, after or concurrently with the second therapeutic agent.
18. The use of claim 17, wherein the second therapeutic agent is selected from the group consisting of an IgE inhibitor, an antibiotic agent, and an anti-fungal agent.
19. The use of claim 17, wherein the second therapeutic agent comprises an intranasal corticosteroid, optionally wherein the intranasal corticosteroid is mometasone furoate nasal spray (MFNS).
20. The use of claim 19, n the second therapeutic agent comprises an inhaled corticosteroid, optionally n the inhaled corticosteroid is fluticasone or budesonide.
21. The use of claim 17, wherein the second therapeutic agent comprises a long-acting beta2 agonist, optionally wherein the long-acting beta2 agonist is salmeterol or formoterol. 17032506_1 (GHMatters) P39476NZ01
22. The use of any one of claims 1-16, wherein the subject has been prescribed or is currently taking a background therapy for nasal polyposis.
23. The use of claim 22, wherein the background therapy is an intranasal corticosteroid.
24. The use of claim 23, wherein the intranasal corticosteroid is mometasone furoate nasal spray (MFNS).
25. The use of claim 22, wherein the background therapy is an intranasal osteroid and a long-acting beta2 agonist.
26. The use of claim 25, wherein the background therapy is fluticasone/salmeterol combination therapy.
27. The use of claim 25, n the ound therapy is budesonide/formoterol combination therapy.
28. The use of claim 22, wherein the background therapy is selected from the group consisting of a nasal saline, a topical decongestant, a topical anesthetic, a leukotriene antagonist, and a systemic antihistamine.
29. The use of any one of claims 6-28, wherein the initial dose is about 400 mg and the one or more ary doses are each about 200 mg.
30. The use of any one of claims 6-28, n the initial dose is about 600 mg and the one or more secondary doses are each about 300 mg.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837912P | 2013-06-21 | 2013-06-21 | |
US61/837,912 | 2013-06-21 | ||
EP14305670 | 2014-05-07 | ||
EP14305670.3 | 2014-05-07 | ||
NZ631118A NZ631118A (en) | 2013-06-21 | 2014-06-20 | Methods for treating nasal polyposis by administering an il-4r antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ752224A NZ752224A (en) | 2020-11-27 |
NZ752224B2 true NZ752224B2 (en) | 2021-03-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019261751B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
US20220204631A1 (en) | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist | |
JP6898421B2 (en) | Method of treating nasal polyps by administration of IL-4R antagonist | |
NZ752224B2 (en) | Methods for treating nasal polyposis by administering an il-4r antagonist | |
JP2021063122A (en) | Methods for treating chronic sinusitis with nasal polyps by administering il-4r antagonist |